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ABSTRACT 
Dogs homozygous for missense mutations in superoxide dismutase 1 
(SOD1) develop a late-onset neuromuscular disorder called degenerative 
myelopathy (DM) that has many similarities to amyotrophic lateral sclerosis 
(ALS).  Both disorders are characterized by widespread progressive declines in 
motor and sensory functions accompanied by atrophic changes in the ascending 
and descending spinal cord tracts. Additionally, some forms of ALS are also 
associated with SOD1 mutations.  In end-stage ALS, death usually occurs as a 
result of respiratory failure due to severe functional impairment of respiratory 
muscles.  The mechanisms that lead to this loss of function are not known.  Dogs 
with DM are euthanized at all stages of disease progression providing an 
opportunity to characterize the onset and progression of any pathological 
changes in the respiratory muscles that may precede respiratory failure.  To 
characterize such potential disease-related pathology we evaluated intercostal 
muscles from Boxer and Pembroke Welsh Corgi (PWC) dogs that were 
euthanized at various stages of DM disease progression. DM was found to result 
in intercostal muscle atrophy, fibrosis, and an alteration in muscle fiber type 
composition.  This pathology was not accompanied by retraction of the motor 
axon terminals from the muscle acetylcholine receptor complexes, suggesting 
that the muscle atrophy did not result from physical denervation. To determine if 
other components of the thoracic motor unit (cell body, axon, and myofibers) also 
demonstrated morphological changes consistent with dysfunction, 
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histopathologic and morphometric analyses were conducted on thoracic spinal 
motor neurons (MNs) and in motor root axons from DM-dogs. Because sensory 
dysfunction is known to occur in DM, dorsal root ganglia (DRG), and sensory root 
axons were also analyzed. No alterations in MNs, or motor root axons were 
observed in either breed. However, advanced stage PWCs exhibited significant 
losses of sensory root axons, and numerous DRG sensory neurons displayed 
evidence of degeneration. These results indicate that intercostal muscle atrophy 
in DM is not preceded by physical loss of the MNs innvervating these muscles, or 
of their axons. Axonal loss in thoracic sensory roots and sensory nerve death 
suggest sensory involvement may play an important role in DM disease 
progression. Results from this investigation support previous findings that DM is 
a multisystem disease with many similarities to human familial SOD1-D90A ALS, 
indicating that DM is a suitable disease model for this form of ALS.  Further 
analysis of the mechanisms responsible for these morphological findings would 
aid in the development of therapeutic intervention for both diseases.   
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CHAPTER 1 
General Overview 
The Motor Pathway 
Amyotrophic lateral sclerosis (ALS) and canine degenerative myelopathy 
(DM) are diseases that affect the central and peripheral nervous systems. The 
central nervous system is composed of the brain and spinal cord, and the 
peripheral nervous system includes cranial and spinal nerves. Motor neurons 
(MNs) such as those found in the motor cortex and brainstem (upper motor 
neurons [UMNs]) possess axons that descend through the spinal cord white 
matter (i.e. corticospinal, rubrospinal, vestibulospinal, reticulospinal tracts), and 
synapse onto interneurons and MNs within the brain stem and ventral horn of the 
spinal cord segments. MN axons of the spinal cord exit the spinal cord as ventral 
(motor) roots and merge with dorsal (sensory) roots at the intervertebral foramen 
to form the spinal nerves.  
A motor unit (MU) consists of a MN cell body, axon, and the associated 
myofibers (Figure 1). The MU functionally is termed lower motor neuron (LMN). 
Alpha MNs have large somas, and innervate extrafusal myofibers. Within the 
alpha MN population exists a range of soma sizes and corresponding axon 
calibers. Generally larger MN’s have larger caliber axons, and innervate fast 
twitch myofibers. They are involved in producing quick bursts of powerful muscle 
contractions, and are quick to fatigue. Conversely, smaller MNs have smaller 
caliber axons that innervate slow twitch myofibers and are fatigue resistant. MU’s  
4 
 
Figure 1. Anatomy of a motor unit. A motor unit consists of (1) a motor neuron, 
(2) its axon, and (3,4) the myofibers it innervates. Handbook of Veterinary 
Neurology, 5th ed. Lorenz MD, Coates JR, Kent M. 
. 
can be further defined by size (i.e. compared to larger MNs, smaller MNs 
innervate fewer, thinner, myofibers and therefore comprise smaller MUs) and 
metabolic properties. Since slow-twitch fibers have large numbers of 
mitochondria, myoglobin, and oxidative enzymes, the aerobic metabolism makes 
them fatigue resistant. These myofibers express the type 1 myosin isoform (type 
1 myofibers) (Swynghedauw 1986). Fast twitch myofibers express the type 2 
myosin isoform (type 2 myofibers) (Swynghedauw 1986), and utilize glycogen, 
whereby anaerobic catabolism makes them susceptible to fatigue (specifically 
type 2B). The intermediate type 2A myofibers are fast twitch /fatigue resistant 
with the capacity to undergo aerobic catabolism. Labeling cross sections of 
muscles can identify the distribution of myofiber types, which even within the 
same individual varies between different muscles, and within the same muscle 
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groups (Johnson et al. 1973). Cross sections of muscles with equivalent amounts 
of each type normally display a “checkerboard” pattern (Armstrong et al. 1982). 
In denervated muscle, the distribution of myofiber types may undergo fiber typed 
grouping. These denervated myofibers become reinnervated by neighboring 
axons, and accordingly express the myosin isoform dictated by its new MN 
innervation (Buller et al. 1960). The histochemical staining result is groups of 
myofibers of the same type. In situations where the MN is unable to reinnervate 
there may be a lack of fiber typed grouping. Thus the affected muscle would 
display groups of myofibers of mixed types. Another histological abnormality is 
the presence of groups or clusters of angular atrophic myofibers that develop as 
a result of denervation, and the scalloped profile is a result of pressure from 
surrounding hypertrophic and/or normal myofibers. Muscle pathology is also 
heavily involved in disease primarily affecting myofibers (i.e. muscular 
dystrophies) (Sewry 2010). Classic features of myopathic disease like muscular 
dystrophies include diffuse variability of myofiber sizes of both fiber types, 
necrosis, extensive fibrosis, and fiber regeneration (Sewry 2010). It has been 
demonstrated that in some hereditary forms of ALS mutant gene expression 
within myofibers has a dominant role in disease pathology (Dobrowolny et al. 
2008; Wong and Martin 2010). Therefore, it is important to distinguish between 
neuropathic and myopathic histopathology.   
In ALS and DM, voluntary motor control is disrupted (Averill 1973; Charcot 
J-M 1869). Voluntary movement is achieved by the convergence of information 
from motor and sensory pathways, via spinal reflexes, and disruption of 
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components and modulators of the reflex arc cause characteristic phenotypes 
important in diagnosis of neurological disorders. Spinal reflexes are unconscious 
and involuntary feedback circuits in which sensory information is relayed to spinal 
MNs, which in turn stimulate the muscle to respond accordingly. For example 
when a muscle is stretched, primary large caliber afferent axons in muscle 
spindles, Ia sensory fibers, become depolarized (Liddell and Sherrington 1924). 
Afferent sensory fibers, which synapse onto MNs and other Ia inhibitory 
interneurons. As a result, MNs of the stretched muscle are excited, and those of 
the antagonist muscle are inhibited through reciprocal inhibition. Consequently, 
the stretched muscle contracts, and the opposing muscle relaxes in an attempt to 
maintain normal length (Liddell and Sherrington 1924). Pathology of any of the 
above reflex components leads to decreased and/or loss of spinal reflexes. 
Additionally, clinical evidence of MU disruption (LMN signs) includes muscle 
weakness, decreased muscle tone, flaccid paralysis, and neurogenic muscle 
atrophy. Spinal reflex evaluations (reduced or absent) are used to localize LMN 
lesions.  
Spinal reflexes are modulated by the UMN pathways. These pathways 
originate in the cerebral cortex and brainstem nuclei and control specific tasks. 
UMNs and relay pathways synapse directly onto MNs or interneurons (I.e. 
inhibitory interneurons) in the spinal grey matter. Thus, descending UMN 
pathways can mediate excitation of specific MN pools controlling contraction and 
relaxation of muscle groups according to the intended movement. Disruptions of 
these pathways lead to UMN signs including spasticity (increased muscle tone 
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and resistance to stretch), slowing of movements (spastic paresis), disuse 
atrophy and hyperreflexia. Presence of UMN and LMN signs and spread of signs 
to other regions within the CNS are used in the clinical diagnosis of ALS and DM, 
and for evaluation of disease progression (Brooks et al. 2000; Coates and 
Wininger 2010).  
Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is the most common group of adult 
motor neuron diseases (Cleveland and Rothstein 2001).  There are many 
variants of ALS, but they all have a number of features in common. ALS is 
generally characterized by progressive muscle wasting, resulting in paralysis and 
death due to respiratory muscle failure (Charcot J-M 1869). Typically ALS affects 
adults 50 years and older, and patients generally succumb to the disease 
process ~3-5 years after onset. There is no cure for any form of  ALS, and 
currently the only FDA approved drug is Riluzole, a drug that provides minimal 
functional benefit to patients (Bensimon et al. 1994). Riluzole is believed to 
primarily assist in modulating glutamate-mediated excitotoxicity (Mizoule et al. 
1985).  Population studies in the U.S.A. indicate ~5,600 people are diagnosed 
per year (15 cases/day), and at any given time ~30,000 Americans are living with 
this disease (Hitsumoto et al. 2006). ALS is 20% more prevalent in men, and 
93% of patients in the ALS CARE database are Caucasian (Hitsumoto et al. 
2006).  
Based on the El Escorial-Revised diagnostic criteria, a definitive diagnosis 
of ALS includes clinical evidence of LMN and UMN dysfunction, and progressive  
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Table 1. Requirements for ALS diagnosis 
spread of symptoms or signs within a body region and to other body regions that 
cannot be explained by other disease processes (Table 1) (Brooks et al. 2000).  
ALS is further classified based on predominance of signs at clinical onset (limb 
verses bulbar), the involvement of LMN and UMN signs at onset (LMN onset, 
UMN onset, bulbar onset), and the rate of progression (rapid, slow)(Kiernan et al. 
2011; Ravits and La Spada 2009). In some ALS patients, abnormalities of 
sensorium has been reported, with symptoms including burning, pain, 
paresthesia, numbness and decreased vibration sensation (Andersen et al. 1996; 
Isaacs et al. 2007; Kawamura et al. 1981; Mulder et al. 1983).  Because 
individuals exhibit various combinations of the above stated clinical features, 
clinical phenotype is heterogeneous (Brooks 1994; Brooks et al. 2000). ALS is 
also genetically heterogeneous (Al-Chalabi et al. 2012). 5-10% of ALS cases are 
familial (inherited) and the remaining are sporadic with no family history (Mulder 
et al. 1986).  Of the familial forms many genes have been identified as causative 
The presence of  
Evidence of LMN degeneration by clinical, 
electrophysiological or neuropathologic examination 
 Evidence of UMN degeneration by clinical examination 
 Progressive spread of symptoms or signs within a region or 
to other regions 
The absence of 
 Electrophysiological or pathological evidence of other 
disease processes that might explain the signs of LMN 
and/or UMN degeneration 
 Neuroimaging evidence of other disease processes that 
might explain observed clinical and electrophysiological 
signs. 
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including SOD1 (Rosen et al. 1993), TARDBP (Gitcho et al. 2008), FUS 
(Laaksovirta et al. 2010), C90rf72 (DeJesus-Hernandez et al. 2011), and 
UBQLN2 (Deng et al. 2011). Because of the clinical and genetic heterogeneity 
associated with ALS, it is believed to be a group of multisystem diseases that 
involve both motor and sensory systems (Heads et al. 1991). 
Histological evaluations of human ALS tissues have identified 
distinguishing neuropathologic features (hallmarks) indicative of MU 
degeneration.  As the term “amyotrophic” implies, muscle wasting is a prominent 
characteristic feature observed in all ALS patients (Charcot J-M 1869), and 
muscle biopsy studies reveal neurogenic muscle atrophy (Andersen et al. 1996; 
Baloh et al. 2007; Fischer et al. 2004; Soraru et al. 2008a; Telerman-Toppet and 
Coers 1978). It has been postulated that the pattern of myofiber type composition 
varies in different forms of ALS (Soraru et al. 2008a). In reports from individuals 
with UMN dominant ALS and individuals with a protracted disease course exhibit 
fiber typed grouping (Andersen et al. 1996; Soraru et al. 2008a), while other 
forms of the disease exhibit general atrophy of groups of fibers (Baloh et al. 
2007).  
A major histopathological feature seen in MUs of ALS patients at end 
stage disease is spinal MN soma loss (Ravits et al. 2007; Wetts and Vaughn 
1996). Surviving MN somas have been noted to display abnormal inclusion 
bodies/aggregates (i.e. Bunina bodies, Lewy body-like inclusions, and hyaline 
inclusions) (Hirano 1991), and morphological features of programmed cell death 
(Martin 1999).  Additionally, ALS patients with mutations in superoxide dismutase 
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1 (SOD1) have aggregates which label positive with antibodies against SOD1 
(Bruijn et al. 1998; Forsberg et al. 2010; Shibata et al. 1996). Drop out of 
myelinated axons, particularly large caliber axons, in motor roots (Hanyu et al. 
1982; Kawamura et al. 1981; Sobue et al. 1981) and spinal nerves (Giannini et 
al. 2010; Perrie et al. 1993) has also been reported.   
Superoxide Dismutase 1 
  Mutations in superoxide dismutase 1 (SOD1) account for 20% of familial 
ALS cases (Rosen et al. 1993). To date, over 160 mutations in SOD1 have been 
recorded as a cause of ALS, spanning all five exons of the gene 
(http://alsod.iop.kcl.ac.uk/). Large efforts have been put into generating 
transgenic rodent models that over express SOD1 mutations for study to provide 
insights into the phenotype and pathogenic mechanisms of ALS.  
 Normal SOD1 Structure and Function  
Superoxide dismutase 1 (SOD1) is a member of an enzyme family that 
works to counter oxidative stress caused by normal cellular metabolism 
(Fridovich 1975; Johnson and Giulivi 2005). This ubiquitously expressed 
cytoplasmic protein has a molecular weight of ~32,000 daltons, consists of 153 
amino acids, and is known as one of the most stable proteins (Fridovich 1975; 
Fridovich 1986; Green et al. 2002; Johnson and Giulivi 2005; McCord and 
Fridovich 1969; Rakhit and Chakrabartty 2006). The SOD1 protein sequence is 
highly conserved across numerous species, including 79% amino acid identity 
between the human, mouse and canine proteins (Figure 2) (Bannister et al. 
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1991; Green et al. 2002; Tainer et al. 1983). The enzyme functions as a 
homodimer, and a disulfide bond connects and stabilizes the two subunits 
(Fridovich 1986; Rakhit and Chakrabartty 2006).   
SOD1 is classified as having a Greek key β-barrel structure, named so 
because diagrams representing the connections between the β-strands are 
reminiscent of designs found in ancient Greek pottery (Figure 3)(Boissinot et al. 
1997). Described as a twisted β-sandwich by Boissinot et. al., each monomer 
consists of 8 antiparallel β-strands, with 4 strands comprising each half of the 
sandwich (Figure 3)(Boissinot et al. 1997; Rakhit and Chakrabartty 2006). The 2 
halves of the sandwich are covalently bound by 2 Greek key loops found at the 
ends of the barrel: the longer more complex loop lies between strands 6 and 7, 
and the shorter loops between strands 3 and 4 (Boissinot et al. 1997).  
Disulfide reduced apo-SOD1 polypeptide, the most immature form of SOD1, is 
properly folded and activated following at least 4 post-translational maturation 
steps: zinc incorporation, copper incorporation, intramolecular disulfide bond 
Figure 2. SOD1 protein sequence homology between humans, mice, and 
dogs (Green et al. 2002) 
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formation, and dimerization (Furukawa and O'Halloran 2006; Rakhit and 
Chakrabartty 2006). Also known as Cu,Zn-SOD, each monomer contains one 
copper (Cu), and one zinc (Zn) ion , which are required for structural stability and 
enzymatic function (Bannister et al. 1991; Fridovich 1986; Johnson and Giulivi 
2005; Rakhit and Chakrabartty 2006). As its name implies, SOD1 catalyzes the 
dismutation of superoxide anions (02
-) (McCord and Fridovich 1969).  
Dismutation describes a specific type of redox reaction in which a substrate is 
reduced and oxidized simultaneously to form 2 different products (McCord and 
Fridovich 1969). This highly conserved enzyme is capable of converting two 
molecules of toxic 02
- into hydrogen peroxide (H2O2) and oxygen (O2)(Figure 3) 
(McCord and Fridovich 1969; Tainer et al. 1983).  
Mutant SOD1 Toxicity in ALS  
Mutations in SOD1 result in the misfolding of the protein (Deng et al. 
1993), and altered protein structure has been linked to diminished dismutation 
activity (Deng et al. 1993; Gurney et al. 1994). In some ALS, however, SOD1 
retains almost normal dismutation activity levels (Andersen et al. 1995; Bruijn et 
al. 1997; Gurney et al. 1994; Wong et al. 1995). Because disease appears to 
occur independent of normal enzyme activity (Bruijn et al. 1997; Fischer et al. 
2012; Gurney et al. 1994; Muller et al. 2006; Wang et al. 2003), it is widely 
accepted that the role of mutant SOD1 in the ALS disease pathogenesis consist 
of a gain of function, rather than a loss of function toxicity (Bruijn et al. 1997; 
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Figure 3. Normal SOD1 structure and function (Boissinot et al. 1997). (A) 
SOD1 has a Greek key topology, named so because diagrams depicting the 
connections of the 8 antiparallel strands resemble designs found on ancient 
Greek pottery. (B) Strands are twisted into a “β-sandwich” with 4 strands 
comprising each half of the sandwich. The 2 halves are covalently bound by 2 
Greek key loops found at the ends of the barrel, and each monomer contains one 
copper and one zinc involved in maintaining structure and function. (C) Normal 
enzymatic function involves the dismutation of superoxide radicals into hydrogen 
peroxide and molecular oxygen 
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Gurney et al. 1994; Ripps et al. 1995; Wong et al. 1995). Of the many SOD1 gain 
of function hypothesis (see (Boillee et al. 2006a) for review) one hypothesis isthat 
mutant SOD1 is capable of interacting with aberrant substrates generating free 
radicals (i.e. peroxynitrate, and hydrogen peroxide) and causing oxidative 
damage to the cell (Beal et al. 1997; Beckman et al. 1993; Ferrante et al. 1997). 
SOD1 null mice are considered to be a model system for studying oxidative 
stress in the MU (Fischer et al. 2012). It was reported that these mice developed 
clinical and histological features consistent with a progressive distal axonopathy 
(Fischer et al. 2012; Muller et al. 2006), and exhibited evidence of limb muscle 
weakness and atrophy (Fischer et al. 2012; Flood et al. 1999; Muller et al. 2006; 
Reaume et al. 1996). They also displayed fiber-typed grouping (Flood et al. 1999; 
Reaume et al. 1996). SOD1 protein aggregation has also been identified as a 
potential factor in the ALS disease process (Deng et al. 2006; Prudencio et al. 
2009; Wang et al. 2003). Cytoplasmic aggregates containing SOD1 have been 
identified in spinal cords from SOD1 associated-ALS patients (Bruijn et al. 1998; 
Kato et al. 2000; Shibata et al. 1996). Using time-lapsed imaging techniques, 
Matsumoto et. al. reported a direct association between aggregate formation and 
cell death in a neural cell line, while cells expressing wild type SOD1 did not 
develop aggregates nor exhibit premature cell death (Matsumoto et al. 2005). 
While said study reported a strong correlation between aggregate formation and 
cell death, this phenomenon may be secondary to disease, and my not represent 
a direct cause and effect. It is postulated that SOD1 aggregation is caused by 
aberrant exposure of hydrophobic surfaces, normally buried within the enzyme, 
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resulting from protein misfolding (Munch and Bertolotti 2010; Zetterstrom et al. 
2007). While wild-type SOD1 has been shown to colocalize with mutant SOD1 
aggregates (Bruijn et al. 1998; Deng et al. 2006; Prudencio et al. 2010), its 
contribution in the disease process still is unresolved. In vitro studies showed that 
overexpression of wild type SOD1 is beneficial in slowing aggregate formation 
(Prudencio et al. 2009). Likewise studies performed in vivo suggests that wild 
type SOD1 overexpression does not cause ALS (Gurney et al. 1994; Ripps et al. 
1995; Wong et al. 1995), or affect disease onset or duration when over 
expressed in mutant SOD1 transgenic mice (Bruijn et al. 1998). Conversely, it 
has also been reported that overexpression of the wild type protein is indeed 
capable of inducing the ALS phenotype (Deng et al. 2006; Jaarsma et al. 2000). 
The pathologic changes of which range from mild histopathologic abnormalities 
(Dal Canto and Gurney 1995) to significant exacerbation of the disease 
phenotype (Deng et al. 2006; Jaarsma et al. 2000; Prudencio et al. 2010). 
Differences in the nature of the SOD1 mutation and wild type expression levels 
used in the fore-mentioned studies could be responsible for the discrepancies 
(Prudencio et al. 2010). Because SOD1 aggregates have been shown to 
sequester and potentially disrupt proteasome function, one proposed mechanism 
by which aggregates may cause cytotoxicity is by disruption of the proteasome 
protein degradation pathway (Matsumoto et al. 2005).  
Additionally, the pathogenesis of ALS is considered to be non-cell 
autonomous, suggesting that mutant SOD1 exerts its toxic effects on multiple cell 
types. Restricted mutant SOD1 expression within astrocytes (Gong et al. 2000), 
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microglia (Beers et al. 2006), or MNs (Lino et al. 2002; Pramatarova et al. 2001) 
alone is not sufficient to induce an ALS phenotype in rodent models. 
Furthermore, mutant MNs within an environment containing wild-type glial cells 
remain protected against neural degeneration (Beers et al. 2006; Clement et al. 
2003). Boliee et. al. reported that mutant SOD1 expression within MNs dictates 
disease onset and early disease stage, while expression within glia is 
responsible for disease progression rates (Boillee et al. 2006b). Also restricted 
expression of mutant SOD1 within myofibers is adequate to produce a MN 
disease phenotype in transgenic mice (Wong and Martin 2010).These studies   
suggest that development of ALS is dependent on aberrant interactions between 
multiple cell types and other pathogenic mechanisms. Studies suggest that  in 
ALS MNs become over stimulated when glutamate is not cleared properly from 
the synaptic cleft by the astrocytic glutamate transporter (GLT-1), resulting in 
neuronal degeneration (Rothstein et al. 1996). Increased CSF glutamate levels 
have been identified in ALS patients (Rothstein et al. 1990; Shaw et al. 1995). 
Likewise decreased GLT-1 levels in transgenic SOD1 rodents (Bruijn et al. 1997; 
Howland et al. 2002) and human ALS patients (Rothstein et al. 1995) have been 
reported.   
SOD1 Transgenic Mouse Models 
Following the discovery that mutations in SOD1 are associated with 
familial ALS cases (Rosen et al. 1993), several transgenic SOD1 rodent models 
over expressing mutations of SOD1 have been generated (Bruijn et al. 1997; 
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Gurney et al. 1994; Jonsson et al. 2006; Ripps et al. 1995; Wong et al. 1995). 
Common ALS-like phenotypes in these transgenic SOD1 rodent ALS models 
include limb weakness and paralysis, and death (Bruijn et al. 1997; Gurney et al. 
1994; Turner and Talbot 2008; Wong et al. 1995). Other clinical signs of MN 
dysfunction include tremor, spasticity, hyperreflexia, positive sharp waves, and 
neurogenic muscle atrophy (Gurney et al. 1994; Ripps et al. 1995; Wong et al. 
1995).   
Histopathology of the MU has also been extensively studied in these 
putative ALS models. These classic pathologies include MN loss, myelinated 
axon loss, myelin degeneration, atrophic myofibers, and evidence of myofiber 
type remodeling (Bruijn et al. 1997; Bruijn et al. 1998; Dal Canto and Gurney 
1994; Fischer et al. 2004; Guegan et al. 2001; Gurney et al. 1994; Jonsson et al. 
2006; Watanabe et al. 2001; Wong et al. 1995). It has been suggested that the 
progression of these features occur in a “dying back” manner (Dadon-Nachum et 
al. 2011; Fischer et al. 2004; Frey et al. 2000). Before clinical onset, myelinated 
axons have been reported to retract from their myofibers, and die back towards 
the cell body (Fischer et al. 2004).  Thus myofibers lose their innervations, 
resulting in denervation atrophy.  As the disease progresses, large myelinated 
axons preferentially degenerate, and decrease in number. End-stage disease is 
accompanied by MN degeneration and loss (Fischer et al. 2004).  
Transgenic SOD1 rodent models have also been used to assist in the 
identification of potential therapeutics for human patients. Unfortunately, 
numerous clinical trials, initiated in part based on promising preclinical results in 
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rodent models, have produced a tremendous amount of disappointment in 
human treatment (Benatar 2007; Morren and Galvez-Jimenez 2012; Scott et al. 
2008). Thus there is growing concern about the utilization of transgenic SOD1 
rodent as disease models for human ALS (Benatar 2007; Gordon and Meininger 
2011).  One suggested limitation of the mouse model is the inapplicable nature of 
many preclinical study designs (Benatar 2007; Scott et al. 2008; Swash 2007).  
For example, a large number of rodent studies initiated treatment before the 
onset of clinical signs, while in human ALS treatment is initiated after clinical 
onset (Benatar 2007; Gordon and Meininger 2011; Swash 2007). Additionally, 
the SOD1G93A mouse, which over expresses the human SOD1 mutation (Gurney 
et al. 1994), has been the standard model used in preclinical studies (Benatar 
2007; Scott et al. 2008); however, it has been noted that mice expressing lower 
copy numbers of the mutant gene more closely embody the human form of the 
disease (Acevedo-Arozena et al. 2011; Dal Canto and Gurney 1997; Henriques 
et al. 2010). Overall, there is a critical need for the identification of preclinical ALS 
models, and the development of applicable study designs that effectively predict 
therapeutic outcomes in people. 
Familial ALS associated with a D90A missense mutation in SOD1 
The inheritance pattern for most familial ALS is autosomal dominant 
(Mulder et al. 1986). Interestingly, ALS patients with the SOD1D90A mutation have 
been associated with both an autosomal dominant (Robberecht et al. 1996), and 
an autosomal recessive (Andersen et al. 1995) inheritance pattern.  Al-Chalabi 
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et. al. suggested these individuals descend from distinct ancestors, such that 
families with the recessive form also inherited a protective modifier, requiring two 
copies of the mutant allele to acquire sufficient toxicity to develop disease (Al-
Chalabi et al. 1998). With a mean age of onset of 45 years and average disease 
duration of 13 years, the homozygous recessive SOD1D90A patients have a very 
stereotyped disease progression (Andersen et al. 1996; Andersen et al. 1995). 
During the “preparetic phase”, individuals experience such symptoms as leg 
stiffness and weakness, muscular cramps and twitches, and sensory 
abnormalities, which includes severe leg /back pain and burning sensations, 
paresthesia, and decreased ability to sense vibration (Andersen et al. 1996).  As 
patients enter the “paretic phase”, they experience progressive asymmetric lower 
limb paresis, general muscle wasting, fasciculation, and loss of spinal reflexes 
(Andersen et al. 1996). Roughly 4 years later symptoms appear in upper limbs, 
succeeded by bulbar symptoms and bladder disturbances (Andersen et al. 
1996). As with most ALS, patients typically die of respiratory failure (Andersen et 
al. 1996).  Spinal MNs contain anti-SOD1 positive cytoplasmic aggregates 
(Forsberg et al. 2010), and muscle biopsies revealed small atrophic fibers and 
fiber typed grouping (Andersen et al. 1996). Also consistent with the ALS 
hallmarks, a sural nerve biopsy revealed loss of large caliber axons and myelin 
pathology (Giannini et al. 2010).  We believe that DM closely resembles disease 
characteristics reported in recessive SOD1D90A. 
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Canine Degenerative Myelopathy (DM) 
DM has many features in common with some forms of ALS. DM is a fatal, 
adult onset, neurodegenerative disease characterized by progressive impairment 
of sensory and motor functions (Averill 1973). Initial clinical signs are seen in 
dogs 8 years and older and include general proprioceptive ataxia and spastic 
weakness in the pelvic limbs. Clinical signs will progress to flaccid tetrapalegia 
and respiratory distress if dogs are not euthanized in early stages of the disease 
(Awano et al. 2009; Coates et al. 2007; Ogawa et al. 2011; Ogawa et al. 2013). 
Time of euthanasia is variable, but most pet owners elect to euthanize once the 
dog can no longer support weight in its pelvic limbs, particularly in larger breed 
dogs (Table 2) (Coates and Wininger 2010). DM is a prevalent disorder in many 
breeds including Boxers and Pembroke Welsh Corgis (PWCs). There are no 
treatments for DM and management of DM affected dogs has been directed 
toward improving quality of life (Coates and Wininger 2010).While it is known that 
DM is associated with mutations in the SOD1 gene, the underlying mechanisms 
resulting in DM pathology are not well understood (Awano et al. 2009).  
For many years DM was believed to only be a disease of the spinal cord 
(Averill 1973; Griffiths and Duncan 1975). At disease onset, UMN weakness is 
displayed as increased muscle tone, and intact spinal reflexes. These clinical 
signs are consistent with disruption of descending motor pathways, and are 
further supported by the presence of neuronal fiber loss in the descending tracts 
and subsequent astrocytic gliosis in the spinal cord white matter (Averill 1973; 
March et al. 2009) . Spinal cord histopathology is most severe in the thoracic  
21 
 
Table 2. Clinical grading scale of disease progression in DM-affected dogs  
* The presumptive diagnosis of DM for dogs was based on the presence and 
progression of these signs. Early stages include grades 1-2, and late stages include 
grades 3-4. (Adapted from (Coates and Wininger 2010; Shelton et al. 2012)) 
spinal cord early in the disease, but spreads cranially and caudally as the 
disease progresses (March et al. 2009). It has only recently been recognized that 
the peripheral nervous system is also affected in DM (Awano et al. 2009; Shelton 
et al. 2012) If euthanasia is delayed, muscle weakness is exacerbated, 
widespread loss of muscle mass is observed, and spinal reflexes become 
reduced to absent. These clinical signs coincide with histopathology of peripheral 
nerve and hind limb muscles. Shelton et. al. showed that DM is associates with 
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significant axon loss and myelin changes in the peroneal nerves of affected dogs. 
This study also revealed evidence of neurogenic muscle atrophy in late stage 
dogs. Changes in myofiber type distribution were apparent in late stage Boxers; 
however, PWC hind limb muscle presented more generalized muscle atrophy 
without type grouping. These findings indicate that the disease processes of DM 
reach beyond the spinal cord (Awano et al. 2009; Morgan et al. 2013; Shelton et 
al. 2012). The purpose of this study was to characterize the phenotype of a 
motor unit involved in respiration in DM-affected dogs. The distribution of 
spinal cord, pelvic limb muscle, peripheral nerve lesions and clinical progression 
in DM are similar to those seen in some forms of SOD1-associated ALS 
(Andersen et al. 1996; Andersen et al. 1995; Awano et al. 2009; Coates and 
Wininger 2010; Giannini et al. 2010; Shelton et al. 2012; Winter et al. 2000). 
Thus we hypothesize that the thoracic MU will exhibit similar histological 
disease hallmarks as some ALS. A thoracic MU was selected for analysis 
because spinal lesions are more severe in the mid thoracic spinal cord in DM 
affected dogs (March et al. 2009). Additionally, spinal segments with intact nerve 
roots are easily accessible from the thoracic cord.  Results from this study will 
increase our understanding of DM and help support whether DM can serve as a 
reliable ALS disease model. Ultimately by broadening our understanding, these 
data could contribute to the later development of effective therapeutic 
interventions for both diseases. 
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CHAPTER 2 
 Characterization of Intercostal Muscle Pathology  
Abstract 
Dogs homozygous for missense mutations in the SOD1 gene develop a 
late-onset neuromuscular disorder called degenerative myelopathy (DM) that has 
many similarities to ALS.  Both disorders are characterized by widespread 
progressive declines in motor functions accompanied by atrophic changes in the 
descending spinal cord tracts, and some forms of ALS are also associated with 
SOD1 mutations. In end-stage ALS, death usually occurs as a result of 
respiratory failure due to severe functional impairment of respiratory muscles.  
The mechanisms that lead to this loss of function are not known.  Dogs with DM 
are euthanized at all stages of disease progression providing an opportunity to 
characterize the onset and progression of any pathological changes in the 
respiratory muscles that may precede respiratory failure.  To characterize such 
potential disease-related pathology we evaluated intercostal muscles from Boxer 
and Pembroke Welsh Corgi dogs that were euthanized at various stages of DM 
disease progression.  DM was found to result in intercostal muscle atrophy, 
fibrosis, increased variability in muscle fiber size and shape, and an alteration in 
muscle fiber type composition.  This pathology was not accompanied by 
retraction of the motor neuron terminals from the muscle acetylcholine receptor 
complexes, suggesting that the muscle atrophy did not result from physical 
denervation.  These findings provide a better understanding of the mechanisms 
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that likely lead to respiratory failure in at least some forms of ALS and will be 
useful in the development and evaluation of potential therapeutic interventions 
using the DM model 
Introduction 
DM is an adult onset neurodegenerative disease characterized by 
progressive impairment of motor functions (Averill 1973).  Initial clinical signs are 
seen in dogs 8 years or older and include loss of coordination and asymmetric, 
spastic weakness in the pelvic limbs, which progress to paraplegia within 1 year 
from clinical onset. If dogs are not euthanized in early disease stages, signs will 
progress to include flaccid tetraplegia, widespread muscle atrophy and difficulty 
swallowing (Coates et al. 2007; Coates and Wininger 2010). Dog owners often 
elect euthanasia when their dogs become paraplegic (Coates and Wininger 
2010), but some are not euthanized until more advanced stages of the disease 
are reached.  
DM has many similarities to some forms of human ALS. Like DM, ALS is 
also an adult onset neurodegenerative disorder characterized by progressive 
loss of motor functions (Andersen et al. 1996; Charcot J-M 1869).  Although 
causes of most ALS cases are unknown, some sporadic and familial forms have 
been associated with mutations in SOD1, which encodes cytosolic Cu/Zn 
superoxide dismutase (Rosen et al. 1993). In 2009, we reported that dogs of 
multiple breeds with a confirmed diagnosis of DM were homozygous for the A 
allele of a SOD1 missense mutation, SOD1:c.118G>A, which predicts p.E40K 
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substitution in SOD1 (Awano et al. 2009). Based on clinical signs, genetic 
testing, and spinal cord histopathology, DM has been found to occur in many 
breeds, and is especially prevalent in Boxers and Pembroke Welsh Corgis 
(PWCs) (Coates and Wininger 2010). Despite growing knowledge of genetic 
associations in ALS, the underlying mechanisms and resulting pathology are still 
not well understood for either the human or canine disease (Al-Chalabi et al. 
2012; Coates and Wininger 2010).  A major impediment to elucidating 
mechanisms underlying disease pathology in ALS is the scarcity of tissues 
available for study. Tissues that are available from ALS patients are usually 
obtained postmortem at end-stage disease.  Thus, pathologic descriptions of 
disease progression in ALS patients are few (Fischer et al. 2004).  With DM, on 
the other hand, dogs are euthanized at various disease stages so tissues can be 
obtained to evaluate progression of disease pathology. 
For many years DM was thought to be a disease that involved primarily 
the ascending and descending tracts of the spinal cord and not the peripheral 
nervous system (Averill 1973; Griffiths and Duncan 1975).  At disease onset, 
spinal reflexes are consistent with UMN dysfunction. Spinal cord pathology is 
most evident in the thoracic spinal cord early in the disease, spreads cranially 
and caudally, and becomes more severe as the disease progresses (Averill 
1973; March et al. 2009). More recently, clinical descriptions and histopathology 
indicate that DM reaches beyond the spinal cord to also involve MUs (MN, axon, 
and myofiber), at least in the advanced stages of disease (Awano et al. 2009; 
Shelton et al. 2012). The distribution of lesions and clinical disease progression 
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in DM are similar to that reported for the UMN-onset ALS, with UMN signs in DM-
affected dogs progressing to lower motor neuron (LMN) signs (Brooks et al. 
2000; Coates et al. 2007; Coates and Wininger 2010). 
To further assess DM as a potential disease model of ALS, studies were 
conducted to evaluate a thoracic MU in DM-affected dogs. We selected this site 
because the pathology in the ascending and descending tracts begins in the 
thoracic region of the spinal cord and because it was anticipated that tissue 
samples could be obtained from this region that represent all stages of DM 
disease progression. Thoracic MUs become impaired in ALS causing failure of 
respiratory muscles (de Carvalho et al. 2010), so evaluation of pathology in this 
region in DM is likely to be relevant to at least some forms of ALS.  
Materials and methods  
Tissue collections 
Tissues were obtained from companion dogs between 2009 and 2013. 
Tissues were acquired from 9 Boxers (4 control ages 8 to13 years; and 5 DM-
affected ages 9 to 12 years) and 20 Pembroke Welsh Corgis (PWCs) (6 control, 
age’s 12 to17 years; and 14 DM-affected, age’s 12 to15 years).  Sample 
collection protocols were approved by the University of Missouri Animal Care and 
Use Committee. Dogs with a presumptive diagnosis of DM, based on clinical 
signs of progressive upper motor neuron paresis and general proprioceptive 
ataxia of the pelvic limbs (Coates and Wininger 2010),  were referred to various 
academic, private specialty or general practices. Dogs were excluded if their 
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clinical signs were associated with spinal cord compressive lesions detected by 
magnetic resonance imaging or myelography or if the dog exhibited clinical signs 
consistent with DM but the histopathology was not typical for a diagnosis of DM 
[(Coates and Wininger 2010) and Figure 4]. Control tissue was obtained from 
age and breed matched unaffected dogs euthanized for causes unrelated to DM.  
Dogs were designated as controls if they had not exhibited clinical signs of DM 
and histological appearance of the thoracic spinal cord tissue was normal (Figure 
4). 
Genotypes at canine SOD1:c.118G>A were determined using blood 
samples from each dog included in the study using a TaqManTM allelic 
discrimination assay that employed  5’-GTGGGCCTGTTGTGGTATCA-3’ with 5’-
CAAACTGATGGACGTGGAATCC-3’ for the PCR primers and 5’-VIC-
CTCGCCTTTAGTCAGC-MGB-3’ (A allele) and 5’-FAM-CGCCTTCAGTCAGC-
MCB-3’ (G allele) for the completing probes (Awano et al. 2009).   
When an owner elected to have a dog euthanized, the veterinarian who 
would perform the necropsy was provided with a kit that included detailed 
instructions and materials for sample collection, preservation and shipping.  
Detailed clinical histories were obtained to document the age at onset and 
progression of clinical signs, neurologic status at the time of euthanasia, and any 
unrelated health problems. Necropsies were performed within 6 hours after 
euthanasia.  Tissues collected included the T6 spinal cord segment fixed in 
buffered 10% formalin, the T7 spinal cord segment fixed in 3.5% 
paraformaldehyde, 0.1% glutaraldehyde, 120 mM sodium cacodylate, 1 mM 
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CaCl2, pH 7.4, and sections of intercostal muscle fixed in 2% glutaraldehyde, 
1.12% paraformaldehyde, 130 mM sodium cacodylate, 1 mM CaCl2, pH 7.4 (EM-
fix), or in cold 0.17 M sodium cacodylate, pH 7.4.  Blood samples for DNA 
isolation were collected in EDTA vacutainer tubes (Becton Dickenson, catalogue 
#367899).   
Disease status determination 
DM-affected dogs were graded based on clinical signs at the time of 
euthanasia as described in Table 2 (Shelton et al. 2012). T6 spinal cord 
segments from all dogs included in this study were paraffin embedded and cut 
into 4 µm thick sections.  These sections were stained with H&E, and luxol fast 
blue-periodic acid Schiff to detect myelin loss.  Immunostaining for glial fibrillary 
acid protein to detect gliosis was performed on dewaxed sections from the same 
blocks using rabbit anti-GFAP antibody (Dako Z0334; Dako, Carpinteria, CA).  
Antibody binding was performed as described below, using Nova Red 
chromogen (Vectorlabs, Burlingame, CA). Diagnosis of DM was 
histopathologically confirmed by observation of profound axonal loss, myelin 
loss, and marked astrogliosis in the dorsal portion of the lateral white matter in 
the thoracic spinal cord (Figure 4) (Averill 1973; March et al. 2009). DM has also 
been characterized by the presence of cytoplasmic aggregates in spinal cord 
motor neurons that bind anti-SOD1 antibodies (Awano et al. 2009; Wininger et al. 
2011) (Figure 4). T7 spinal cord segments were examined for the presence of 
these aggregates. To detect SOD1-containing cytoplasmic aggregates, dewaxed  
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Figure 4. DM affected spinal cords displaySOD1 positive aggregates in 
motor neurons, and marked myelinated axon loss in white matter. 
Immunohistochemical demonstration of SOD1-containing aggregates in motor 
neurons in the thoracic spinal cord (A,B). Numerous aggregates stained with an 
antibody directed against SOD1 were present in ventral horn motor neurons from 
a DM-affected PWC (B).  Similar aggregates were present in all affected dogs of 
both PCW and Boxer breeds. These inclusions were not observed in thoracic 
cord motor neurons from unaffected dogs (representative preparation from a 
control PWC shown in B). Luxol fast blue and periodic acid-Schiff stained 
thoracic spinal cord from unaffected (C) and grade 4 (D) PWCs. Pallor of the 
peripheral white matter in (D) corresponds to axonal loss and demyelination 
(arrows).  Higher magnification of thoracic white matter from unaffected (E) and 
grade 4 (F) PWCs stained with toluidine-blue. Substantial axonal loss with myelin 
pathology is seen in the PWC with advanced DM.  Bars in (A), (C) and (E) 
indicate magnifications in (B), (D) and (F) respectively  
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paraffin sections of the T7 spinal cord segment from DM-affected dogs and 
controls were prepared as described above, incubated overnight at 43oC, then 
hydrated and steamed at 95oC for 20 minutes in pH 6.0 citrate buffer.  After the 
slides were cooled at room temperature for 20 minutes and rinsed, they were 
placed in Tris buffer for at least 5 minutes before immunostaining.  Next, the 
slides were treated with 3% H202 for 15 minutes, washed in buffer, submerged in 
Protein Blocking solution (Dako) for 5 minutes and drained.  They were then 
incubated in rabbit anti-SOD1 antibody, (Stressgen SOD100) at a 1:800 dilution 
for 60 minutes at room temperature.  Negative controls were treated for 60 
minutes with nonimmune rabbit IgG (Sigma, St. Louis, MO) at a 1:1000 dilution in 
place of the anti-SOD1 antibody.  Antibody binding was visualized with the 
Rabbit Envision+ kit (Dako).  The chromogen was Nova Red.  Slides were then 
counterstained in Mayer’s Hematoxylin (Newcomer’s Supply, Appleton, WI) for 1 
minute, dehydrated and cover slipped.  Each immunohistochemical specimen 
was evaluated with and without primary antibody included in the immunostaining 
procedure to verify the specificity of staining. 
Myofiber type grouping and neuromuscular junction analysis 
Unfixed intercostal muscles preserved in 0.17 M sodium cacodylate, pH 
7.4, were cryo protected by sequentially incubating in 10% sucrose (in 0.17 M 
sodium cacodylate), 20% sucrose (in 0.17 M sodium cacodylate), and 1:1 20% 
sucrose: optimum cutting temperature (OCT) solution (OCT, Tissue-Tek, Sakura 
Finetek, Torrance, CA) for at least 45 minutes each. Samples were then placed 
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in a plastic mold containing 100% OCT medium, oriented so that muscle fibers 
could be cut in cross section for myosin heavy chain type 1 (MHC-1) staining, 
and longitudinally for neuromuscular junction (NMJ) labeling. Molds were 
incubated on ice for at least 45 minutes, and then transferred quickly to a dry ice 
block for freezing. Frozen sections were cut at a thickness of 10-12µm or 20-
30µm for MHC-1 and NMJ labeling respectively. Sections were mounted on 
Superfrost/PlusTM slides (Fisher Scientific #12-550-15). Slides were washed in 
1X PBS (Fisher Scientific, Catalog # BP665-1) for 5 minutes before labeling.   
Myofiber Type grouping assay.  
Endogenous peroxidase was quenched by incubating slides in 3% 
hydrogen peroxide for 5 minutes at room temperature. Slides were then rinsed in 
phosphate buffered saline (PBS) (900ml H20, 100ml 10x PBS) two times for 5 
minutes each, blocked for 1 hour in 5% normal goat serum, incubated with 
myosin heavy chain 1 antibody (DSHB, Catalog # BA-D5-s) diluted 1:10 
overnight at 4⁰C, rinsed in PBS for 5 minutes 3 times, and incubated with goat 
anti-mouse IgG horseradish peroxidase conjugate (Invitrogen, Catalog # A-
10677), diluted 1:10 for 1 hour at room temperature. Slides were than rinsed in 
PBS 2 times for 5 minutes each, and incubated in diaminobenzidine (DAB, 
Millipore Catalog number ES005) for 5 minutes at room temperature. With this 
technique, type 1 fibers stain darkly and type 2 fibers remain unstained. Light 
microscopy was used to image the entire muscle cross section at a 100x 
magnification. Each composite image of a muscle section consisted of individual 
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image frames stitched together.  The frames were acquired by moving the 
specimen past the microscope objective in a raster pattern using an automated 
stage.  Overlapping images of all areas of the section were captured in this 
manner and stitched into a composite image of the entire section by the Leica 
software.  Proportions of type 1 fibers were calculated from individual frames 
using ImageJTM software. For each sample, two frames were randomly selected 
from each vertical pass of the stage during automated stitching (6-14 
frames/sample section depending on size of the cross section). This method of 
sampling was used to acquire data representative of multiple fascicles within 
each muscle cross section.   
Evaluation of neuromuscular junctions (NMJs). 
The intercostal muscles were evaluated for contact between neurons and 
the muscle acetylcholine receptor (AChR) complexes (Fischer et al. 2004). 
Cryostat sections of the cacodylate-preserved muscle specimens were incubated 
with alpha bungarotoxin conjugated to AlexaFluor 594 (Invitrogen, Catalog # B-
13423) diluted 1:100 in DI water with 2mM of sodium azide for 45 minutes at 
room temperature in the dark, then rinsed for 20 minutes in PBS. Slides were 
then blocked in 5% normal goat serum with 0.9% triton for 1 hour in a humidified 
chamber, excess blocking reagent was removed, slides were incubated in a 
humidified chamber overnight in 4⁰C with anti neurofilament –light (NF-L) 
antibody (Millipore, Catalog # AB9568 ) diluted 1:800 in 5% normal goat serum.  
The sections were then washed 3 times in PBS for 5 minutes each. Secondary 
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antibody (Invitrogen, AlexaFluor 488 conjugated goat-anti rabbit  IgG, Catalog # 
A-11034), diluted 1:100 in  PBS, was applied and the samples were incubated at 
room temperature in a humidified chamber for 1 hour in the dark. Slides were 
then washed 3 times in PBS for 5 minutes each, mounted with anti-fade 
mounding media (Biomedia corp, Gel/Mount aqueous mounting medium with 
anti-fading agents) and imaged at a 200x magnification. With this technique the 
muscle AChR’s are visualized by the red emission and the axons of the neurons 
are visualized by the green emission.  At least 100 AChR complexes per sample 
were imaged, and these complexes were examined for the proximity of nerve 
terminals labeled with the anti-NF-L antibody.  Images derived from the red and 
green channels were layered in PhotoShop, and transparency adjusted to assess 
the co-localization of labels. Neuromuscular junctions were scored as intact 
(continuous NF-L label overlapping with bungarotoxin label), partially intact 
(fragmented NF-L label adjacent to or co-localizing with bungarotoxin label), or 
absent (bungarotoxin label with no adjacent NF-L label).  
Morphometric analysis of myofibers 
4 micron thick paraffin cross sections were obtained from EM-fixed 
intercostal muscle.  Sections were cut perpendicular to the long axis of the 
muscle fibers, and were stained with H&E and Masson trichrome using standard 
methods. Masson trichrome labeling was used to assess whether fibrosis of the 
intercostal muscle occurs in DM. Light microscopic images of the sections were 
obtained at a 200x magnification. FijiTM or PhotoshopTM imaging software were 
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used to generate a black and white segmented mask (Figure 5. B). In 
PhotoshopTM, the mask was overlaid on the gray-scaled original image, 
transparency increased, and manual corrections made to define the boundaries 
of each fiber (Figure 5.C). Once boundaries are defined, the corrected mask was 
thresholded in FijiTM, and a particle analysis tool was used to obtain 
measurements. Morphometric measurements were obtained from at least 100 
myofibers per sample and included minor axis length, cross-sectional area, and 
% of angular fibers (Soraru et al. 2008a; Victor Dubowitz 2007 Brand 1982). The 
minor axis length is identified as the shortest axis of a best-fit ellipse for each 
fiber (Figure 5.D). A blind assessment of myofiber angularity was done manually 
to determine the percent of angulated fibers. Angulated myofibers were defined 
as those with one or more angles of less than 45 degrees (Inset in Figure 5.C). 
Light and fluorescence microscopy 
 Muscle histological sections were imaged using a Leica DMI 6000B 
inverted microscope equipped with an automated stage and Leica application 
suite advanced fluorescenceTM software (LAS-AF) program. For histopathological 
evaluations, sections were examined using transmitted white light illumination.  
Images were acquired using a 20 X objective, and individual images were 
stitched together using the automated stage in combination with the Leica 
software to create a single high-resolution image of the tissue cross sections 
(when large areas were to be analyzed for morphological changes).  Specimens 
stained with fluorescent probes were examined with the same microscope using 
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epi-illumination.  To visualize AlexaFluor 594 fluorescence Leica filter cube TX2 
ET was utilized (excitation filter band pass [BP] = 560/40; emission filter BP 
645/75).  To visualize AlexaFluor 488 fluorescence Leica filter cube L5 ET was 
used (excitation filter BP = 480/40; emission filter BP 527/30).  
Statistical analyses 
The data for Boxers and PWCs were analyzed independently.  Data were 
analyzed for normality using a Shapiro-Wilk normality test. All data passed the 
normality test, thus Student’s t-test was employed to compare affected and 
unaffected dogs 
Results 
SOD1 genotypes  
Genotyping results for all dogs are summarized in table 3. All DM-affected PWCs 
were homozygous for the A allele. Six unaffected PWCs had varying genotypes, 
including three that were homozygous for the A allele (Table 3).  All 5 DM-
affected Boxers were homozygous for the A allele.  Unaffected Boxers had 
varying genotypes, including one homozygous for the A allele (Table 3).  Of the 
unaffected PWCs homozygous for the A allele, all were 12 years and older at the 
time of euthanasia.  The unaffected Boxer homozygous for the A allele was 9 
years old when euthanized. 
Intercostal muscle changes in late-stage DM dogs 
Myofibers from unaffected PWCs and Boxers were generally uniform in 
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Figure 5. Methods for morphometric analysis of myofibers (A) Hematoxylin 
and eosin stained intercostal muscle cross sections were imaged with light 
microcopy at a 200x magnification. (B) FijiTM or PhotoshopTM imaging software 
were used to generate a black and white segmented mask outlining the 
boundaries of each myofiber. (C) In PhotoshopTM, the mask was overlaid on the 
gray-scaled original image, transparency increased, and manual corrections 
were made to define the boundaries of each fiber. Once boundaries are defined, 
the corrected mask is thresholded in FijiTM, and a particle analysis tool was used 
to obtain measurements. Measurements include minor axis length, fiber cross 
sectional area, and roundness. (D) The minor axis is identified as the shortest 
axis of a best fit ellipse (Arrow). Pixels of this axis and of the cross sectional 
areas were converted to µm and µm2 respectively for each myofiber.  The 
percent of angulated fibers (example labeled with “a” in insert of panel C) were 
determined manually by a masked evaluator. 
. 
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Table 3. SOD1 genotypes 
Number of Dogs of Each SOD1 Genotype 
 (age in years) 
Disease Status - 
Breed 
G/G A/G A/A 
Unaffected PWC 1 (16) 2 (14, 17) 3 (12 to 14) 
Affected PWC 0 0 14 (12 to 15) 
Unaffected Boxer 1 (8) 2 (12, 13) 1 (9) 
Affected Boxer 0 0 5 (9 to 12) 
size and shape (Figure 6), with some variability typical of old age (Braund et al. 
1982b). For both breeds, myofibers from early disease stage dogs were similar in 
appearance to those from controls (Figure 6. A). Severe atrophic changes were 
consistently seen in Grade 4 PWC muscle (Figure 6. C and D). Similar atrophy 
was occasionally seen in grade 3 PWC, but not in Grade 3 Boxers or in Grade 2 
dogs from either breed. No Grade 4 Boxer intercostal muscles were available for 
this analysis. Collagen labeling was occasionally seen within myofiber fascicles 
of Grade 4 PWCs (Figure 6. D).      
Increased variability in PWC intercostal myofiber size and shape 
Individual myofibers were much more variable in size and shape in PWCs 
with end-stage DM than in age-matched unaffected dogs (Figure 7).   Size 
histograms depict apparent differences in the distribution of the minor axis and 
area measures of fiber sizes of control and affected PWC myofibers (Figure 7. A 
and D). When data were divided into early and late disease groups (Figure 7. B 
and E), there was a larger percentage of myofibers with larger minor axis’s in  
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early stage, and a larger percentage of myofibers with smaller minor axis’s in late 
stage PWC. There was no statistical significance between the mean myofiber 
minor axes or areas of control and affected PWCs.  However, among PWCs 
there was a significantly larger range of myofiber sizes in the muscles from DM 
dogs compared to those from unaffected dogs (minor axis length range; control= 
Figure 6. Severe pathology in intercostal muscle of late stage DM dogs 
Intercostal muscles were stained with H&E (A and C), and Masson trichrome (B 
and D), to visualize general morphology of myofibers and presence of fibrotic 
tissue. (A and B) Myofibers from a control PWC display uniform size and shape 
with no fibrosis seen between fibers. (C) Myofibers from a grade 4 PWC showing 
variability in size and shape with hypertrophy (long arrow) and atrophy (short 
arrow) fibers. (D) Late-stage PWC displaying fibrosis (blue stain). 
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28.2 µm, affected = 43.4 µm: p <0.001, area range; control =1,737 µm2 affected= 
2,8491 µm2: p = 0.039) (Figure 7. C and F). The percentage of angulated 
myofibers was on average larger in grade 4 PWC muscle than in unaffected 
PWCs (Control= 7.7% ± 3.5% (n= 6 dogs), affected = 14.5% ± 6.9% (n=4 dogs); 
p= 0.068). These data support the abnormal deviation from uniform fiber sizes 
seen in figure 6, and coincide with the observation of abundant small atrophic 
fibers and large hypertrophic fibers in Grade 4 intercostal muscle.   
Among Boxers, there were no differences in fiber size distributions 
between affected and unaffected dogs (Figure 8). However there was a peak in 
the medium-size range of both minor axis length and area parameters in early 
disease samples that was not present in the normal or late stage dogs (Figure 8 
B and E).  
Acetylcholine receptor (AChR) complexes remain innervated in DM affected 
intercostal muscle 
Because atrophic myofibers are a prominent feature in late stage PWC 
intercostal muscle, we evaluated muscle AChR complexes to determine if they 
maintained close proximity with nerve terminals (Figure 9 A-C).  No differences 
were seen between the percentages of intact, partially intact, or absent axons 
from affected and control dogs (Figure 9. D).   
End stage intercostal muscles display shift to type 1 myofiber predominance 
Unaffected and early stage Boxer and PWC muscles retained a normal 
checkerboard pattern of type 1 and type 2 fibers distributions (Figure 10. A). Late 
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.   
Figure 7. Morphometric data reveal increased variability of intercostal 
myofiber sizes in DM-affected PWC. (A, D) Size distribution graphs of 
myofibers from affected PWCs  show changes in the distribution of fibers sizes 
(minor axis, and cross sectional area respectively).  (B, E) Distribution graph of 
affected PWCs separated into early (n = 3) and late (n=9) stages. Early stage 
myofiber distributions were shifted towards larger size classes, while more small 
fibers were seen in the late stage distribution. (C, F) No significant difference was 
seen between the mean minor axis lengths or cross sectional area of unaffected 
and affected dogs; however the range of fiber sizes were significantly increased 
in affected PWCs  (* p<0.05). 
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Figure 8. Boxer morphometric data reveal no significant differences in 
intercostal myofiber sizes. (A, D) Size distributions of minor axis length and 
cross-sectional area of myofibers from unaffected and affected samples. (B, E) 
When affected dog data is separated into early and late stage (early: n=2, Late: 
n=2), early disease samples exhibit a peak in the medium size range.  (C, F) No 
significant differences were detected in mean minor axis length or range between 
control and affected groups.  
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stage PWC samples displayed a dramatic shift to a predominance of type 1 
fibers (Figure 10. B). The percentages of type 1 myofibers in an unaffected and 
grade 3 PWC samples were similar (Unaffected: 32%, grade 3, 39% and 38%). 
In two grade 4 PWCs, the percentage of myofibers that were of type 1 were 67% 
Figure 9. Acetylcholine receptor (AchR) complexes remain innervated in 
DM-affected intercostal muscle. Thoracic intercostal muscle from one 
unaffected and six affected dogs were stained with alpha bungarotoxin to label 
AChR’s (red), and anti-NF-L to label axon terminals (green). At least 100 
complexes were imaged from each sample. Axons were scored based on 
proximity to AChR complexes as intact (A), partially intact (B), or absent (C).  (D) 
Bar graph showing the percentage of receptors from each sample that were 
intact, partially intact, or absent.  Insert in A is a higher magnification showing 
contact between the nerve terminal and the receptor complex. A-C are 
representative images of observations from control and affected samples. 
43 
 
and 76%. Two Boxers, grade 2 and 3 had moderately higher proportions of type 
1 myofibers (59% and 65%, respectively) than the one unaffected Boxer (49%). 
The control and Grade 3 Boxers had higher proportions of type 1 fibers 
compared to the PWCs with the same disease statuses. Only a limited number of 
 samples suitable for these analyses were available because MHC-1 
immunolabeling was hindered by formalin fixation. 
Figure 10. Changes in fiber type patterns in intercostal muscle of late stage 
DM dogs. Intercostal muscles were stained with anti-myosin heavy chain-1 to 
visualize the proportions of fiber types. (A) Unaffected PWC with normal 
checkerboard pattern of type 1 and 2 fibers. (B) Grade 4 PWC with a high 
predominance of type 1 fibers. Bar in (A) represents magnification in both 
images. (C) Bar graph displaying % of type 1 myofibers in PWC (left) and Boxer 
(right) thoracic intercostal muscle. PWC graph correlates with observations, with 
a larger percentage of type 1 fibers in grade 4 dogs (control n = 1, affected n = 
4). (Boxers: control n= 1, affected n =2). 
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Discussion  
 Muscle atrophy is a classic and progressive feature in ALS patients and 
has also been reported in SOD1 transgenic mouse models (Andersen et al. 
1996; Charcot J-M 1869; Gurney et al. 1994; Wong et al. 1995). Our data 
indicate that this atrophy is recapitulated in the intercostal muscles in canine DM. 
The DM-related changes in muscle morphology are consistent of those 
associated with denervation atrophy, suggesting neurogenic pathology due to 
altered motor neuron input to the muscle (Shelton et al. 2012).  However there 
did not appear to be loss of physical contact of the motor nerve terminals with the 
intercostal muscle fibers. Among dogs with DM at the stages evaluated in this 
study, the disease is not accompanied by a loss of motor neurons from the 
thoracic cord or decreases in the numbers of motor axons in thoracic cord motor 
nerve (March et al. 2009).  Therefore, if muscle atrophy was secondary to altered 
neural input, it appears that the cause must be primarily impaired motor neuron 
function without gross structural changes in the motor nerve terminals, axons or 
cell bodies.  The finding that the neuromuscular junctions remain physically intact 
differs from findings in  some SOD1 transgenic mouse models in which loss of 
contact between motor neuron terminal processes and muscle acetyl choline 
receptor complexes has been reported (Dadon-Nachum et al. 2011; Fischer et al. 
2013; Fischer et al. 2004; Frey et al. 2000; Schaefer et al. 2005).   
In a recent study, electrodiagnostic evaluations of dogs with DM indicated 
functional impairment of pelvic limb muscles in early disease stages when dogs 
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become nonambulatory, whereas histopathological evidence of denervation was 
not apparent until advanced disease stages (Shelton et al. 2012). Similar findings 
have been described in some ALS and Charcot-Marie-Tooth mouse models 
where abnormal motor function and muscle pathology existed without significant 
physical evidence of denervation (Lobsiger et al. 2005; Shen et al. 2011). In ALS 
patients, electrodiagnostic evaluation of diaphragm and intercostal muscles 
revealed fibrillation sharp waves, indicative of denervation, which correlated with 
respiratory muscle weakness (de Carvalho et al. 2010). Whether there is a 
similar physical preservation of the neuromuscular junctions in human ALS 
intercostal muscles remains to be determined.  This will be important to evaluate 
with respect to further assessing both DM and SOD1 transgenic mice as models 
for ALS. 
In comparing pathological changes associated with DM or ALS, it is 
important to note that similar changes may occur at different stages of the 
disease in different muscle groups and in the nerves associated with these 
muscles. Weakness and atrophy of limb muscles are relatively early to mid-stage 
signs of both ALS and DM, whereas respiratory impairment is a relatively late 
manifestation of these diseases.  Therefore, the intercostal muscles evaluated in 
this study most likely represent the earlier phase of the degenerative process and 
therefore provide information on a different stage of the pathogenesis than the 
hind limb muscles obtained at the same disease stages (Shelton et al. 2012).  
Likewise, the fibular nerve pathology reported in DM (Shelton et al. 2012) may be 
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more advanced at the same disease stage than any pathology that might be 
present in nerves associated with the intercostal muscles. 
It has been widely reported that neurogenic atrophy in muscle from ALS 
patients is accompanied by fiber-type grouping, postulated to occur when 
denervated myofibers are reinnervated by collateral sprouts from neighboring 
axons (Andersen et al. 1996; Fischer et al. 2004; Schaefer et al. 2005; Soraru et 
al. 2008a). On the other hand, it has also been reported that muscle biopsies 
from ALS patients exhibit muscle fiber atrophy but no fiber type grouping (Baloh 
et al. 2007).  The reason for this apparent discrepancy is not apparent from the 
data available, but ALS actually encompasses a spectrum of disorders, and it is 
possible that fiber type grouping occurs in some forms of the disease and not 
others (Soraru et al. 2008a).  The pronounced increase in the ratio of type 1 to 
type 2 fibers seen in end stage PWCs, relative to that in a normal PWC, has also 
been reported in hind limb muscle from an ALS mouse model with a low copy 
number of a mutant SOD1 transgene (Acevedo-Arozena et al. 2011). This 
change could result from fiber-type remodeling.  Alternatively, DM may result in a 
preferential loss of type 2 fibers.  In ALS mouse models, myofibers expressing 
the type 1 myosin isoform are more resistant to disease (Acevedo-Arozena et al. 
2011; Frey et al. 2000; Hegedus et al. 2007). This could also be the case for the 
intercostal muscles in DM and in at least some forms of ALS.  
Although the fiber type composition was evaluated in a limited number of 
dogs in the present study, it appears that there may be significant breed 
differences in distribution of fiber types in the intercostal muscles (Armstrong et 
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al. 1982).  Thus, for evaluation of disease progression in DM, it appears that data 
from different breeds should not be pooled.   Because PWCs tend to be 
euthanized at all stages of the disease process whereas very few Boxers are 
maintained until disease end stage, it would be more practical to focus future 
studies on the PWC breed as a disease model. 
In DM histopathology, both in the intercostal muscles and in pelvic limb 
muscles, occurs late in the disease process (Shelton et al. 2012), suggesting that 
DM may be a very useful model for studying the mechanisms underlying the 
development of muscle pathology in ALS.  Tissue samples available from ALS 
patients, particularly nervous tissues, have primarily been collected postmortem 
from patients who died as a consequence of the disease and not prior to the 
development of advanced histopathology.  On the other hand, tissue samples 
can be collected from PWCs at all stages of DM disease progression.  Larger 
breed (Boxers) dogs are usually euthanized when nonambulatory paraparesis 
develops so tissues representing late stage disease are difficult to obtain from 
this or other larger breed with DM. Functional and biochemical analyses of early 
stage muscle and nerve is likely to provide insight into the process that 
culminates in the types of late-stage muscle histopathology characteristic of both 
DM and ALS. 
In this study, we found that not all dogs homozygous for the SOD1 
mutation develop DM and none of the dogs that were heterozygous for this 
mutation developed the disease. In a cohort of 239 dogs of multiple breeds that 
were homozygous for the A allele and over 9 years of age, 25 had not exhibited 
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signs of DM (unpublished data).  This is consistent with a previous report that this 
SOD1 mutation in DM is associated with an incompletely penetrant autosomal 
recessive mode of inheritance (Awano et al. 2009). Similarly, it has also been 
reported that the D90A- SOD1 mutation in ALS patients can be inherited in an 
autosomal recessive and incompletely penetrant pattern (Al-Chalabi et al. 1998; 
Andersen et al. 1996; Andersen et al. 1995; Khoris et al. 2000). Patients with the 
adult onset recessive form of ALS are speculated to have also inherited a 
protective modifier, tightly linked with SOD1, from a common ancestor (Al-
Chalabi et al. 1998). This hypothetical modifier is proposed to decrease the 
toxicity of the mutant allele so that two copies are required to produce an ALS 
phenotype. The existence of a hypothetical modifier similar to that which has 
been proposed for ALS could also explain why some dogs that are homozygous 
for the SOD1:c.118G>A mutation fail to develop DM, even at advanced ages. 
Determining why some dogs that are homozygous for the SOD1 mutation fail to 
develop DM may provide clues on how to prevent or delay the development and 
progression of DM in dogs and ALS in people with predisposing SOD1 
mutations.  
Overall these studies indicate that DM may be a very useful model in 
elucidating the mechanisms underlying neuromuscular pathology in at least 
some forms of ALS.  The muscle pathology in the canine disease recapitulates 
that which occurs in the human disorder. The ability to obtain tissues from 
affected dogs in the early stages of the disease process will enable 
characterization of the pathogenesis of disease progression that is not possible 
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with ALS.  DM is also likely to be a good disease model for evaluating potential 
therapeutic interventions for some forms of ALS  
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CHAPTER 3 
 Characterization of Thoracic Motor and Sensory Neurons and 
Spinal Nerve Roots  
Abstract 
Canine Degenerative Myelopathy (DM) is a progressive adult-onset 
multisystem degenerative disease with many features in common with 
amyotrophic lateral sclerosis (ALS).  As with some forms of ALS, DM is 
associated with mutations in superoxide dismutase 1 (SOD1). Clinical signs 
include general proprioceptive ataxia and spastic upper motor neuron paresis in 
pelvic limbs, which progress to flaccid tetraplegia and dysphagia.  The purpose of 
this study was to characterize DM as a potential disease model for ALS. We 
previously reported that intercostal muscle atrophy develops in dogs with 
advanced stage DM. To determine if other components of the thoracic motor unit 
(MU) also demonstrated morphological changes consistent with dysfunction, 
histopathologic and morphometric analyses were conducted on thoracic spinal 
motor neurons (MN) and dorsal root ganglia (DRG), and in motor and sensory 
nerve root axons from DM-affected Boxers and Pembroke Welsh Corgis (PWCs). 
No alterations in MNs, or motor root axons were observed in either breed. 
However, advanced stage PWCs exhibited significant losses of sensory root 
axons, and numerous DRG sensory neurons displayed evidence of 
degeneration. These results indicate that intercostal muscle atrophy in DM is not 
preceded by physical loss of the motor neurons innvervating these muscles, or of 
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their axons. Axonal loss in thoracic sensory roots and sensory nerve death 
suggest sensory involvement may play an important role in DM disease 
progression.  Further analysis of the mechanisms responsible for these 
morphological findings would aid in the development of therapeutic intervention 
for DM and some forms of ALS 
Introduction 
Canine degenerative myelopathy (DM) is a hereditary neurodegenerative 
disorder with onset of clinical signs occurring in dogs 8 years or older (Averill 
1973). Clinical signs appear in pelvic limbs as spastic upper motor neuron (UMN) 
paresis and general proprioceptive ataxia, which progresses to flaccid tetraplegia 
and dysphagia if euthanasia is delayed (Coates and Wininger 2010). Like some 
forms of familial amyotrophic lateral sclerosis (ALS) DM is associated with 
mutations in SOD1 (Andersen et al. 1996; Coates and Wininger 2010); (Morgan 
et al. 2013). DM occurs in many breeds and is typically accompanied by the 
SOD1 missense mutation SOD1:c.118G>A, which predicts a p.E40K substitution 
(Awano et al. 2009).  The clinical signs, disease progression, and muscle 
pathology in DM are similar to those seen in some forms of human SOD1-ALS.  
Thus it appears that DM may potentially be a good disease model for some types 
of ALS. 
In ALS patients who receive extensive palliative care, death usually results 
from failure of respiratory muscle function, typically within 3-5 years after clinical 
onset. While many ALS patients are medically managed and survive for relatively 
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long periods in severely debilitated states with respiratory and feeding 
assistance, DM affected dogs are usually euthanized at earlier disease stages 
often due to ambulatory impairments. However, some DM-affected dogs are 
maintained until respiratory dysfunction develops (Ogawa et al. 2011; Ogawa et 
al. 2013). Therefore, both ALS and DM are characterized by the occurrence and 
progression of UMN and lower motor neuron (LMN) signs, which ultimately result 
in flaccid tetraplegia and respiratory failure (Brooks et al. 2000; Coates and 
Wininger 2010; Ogawa et al. 2011; Ogawa et al. 2013) (Table 2). 
Histopathological similarities between DM and ALS include myelinated axon loss 
and gliosis within the spinal cord, myelinated axon loss in peripheral nerves and 
muscle atrophy. Accumulations of cytoplasmic aggregates containing SOD1 
within motor neurons (MNs) also occurs in DM and some forms of ALS 
(Andersen et al. 1996; Awano et al. 2009; Charcot J-M 1869; Forsberg et al. 
2010; Hirano 1991; Shelton et al. 2012; Sobue et al. 1987) (Morgan et al. 
2013;(Averill 1973; Giannini et al. 2010)). Although ALS is generally considered 
primarily a disease of the motor system, there is growing evidence indicating 
sensory involvement (di Trapani et al. 1986; Dyck et al. 1975; Guo et al. 2009; 
Heads et al. 1991; Isaacs et al. 2007; Kawamura et al. 1981; Mulder et al. 1983; 
Pugdahl et al. 2007). Sensory deficits are also characteristic features of DM 
(Averill 1973). 
 Although the degenerative changes in the spinal cord neuronal fibers 
have been known for some time (Griffiths and Duncan 1975); (Averill 1973), LMN 
involvement in DM is a relatively new finding (Awano et al. 2009; Coates et al. 
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2007; Shelton et al. 2012). We recently reported that intercostal and pelvic limb 
muscles from Pembroke Welsh Corgis (PWCs) at late stage disease exhibited 
marked pathological changes consistent with denervation atrophy (Morgan et al. 
2013; Shelton et al. 2012). Also, thoracic MNs that innervate the intercostal 
muscles contain cytoplasmic aggregates that stain with an anti-SOD1 antibody 
(Awano et al. 2009; Morgan et al. 2013). The degenerative changes in the 
intercostal muscles suggest that thoracic motor units are dysfunctional in DM, 
and may result from impaired MN input to these muscles. In most forms of ALS 
loss of spinal MNs and axonal degeneration are considered disease hallmarks 
(Hirano 1991; Sobue et al. 1981), and loss of MN input appears to play an 
important role in the pathology that develops in the associated muscles. To 
assess whether the thoracic muscle atrophy in DM is also associated with MN 
defects, morphometric analyses were performed on thoracic MNs and motor 
axons from DM-affected dogs and age-matched control dogs.  In addition, 
evaluations were performed to determine whether DM is accompanied by 
alterations in the thoracic sensory nerves and their axons 
Materials and methods  
Tissue collections from dogs 
Tissues were obtained from companion dogs between 2009 and 2013. 
Samples were acquired from 14 Boxers (6 control ages 8 to 12 years; and 9 DM-
affected ages 10  to 12 years) and 21 Pembroke Welsh Corgis (PWCs) (7 
control, ages 13 to 17  years; and 15 DM-affected, ages 12 to 15 years) (Table 
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4).  Dogs were diagnosed with presumptive DM at academic, private specialty or 
general practices based on clinical presentation and progression of upper motor 
neuron and lower motor neuron signs, and general proprioceptive ataxia that 
began in the pelvic limbs (Coates and Wininger 2010).  Histopathological 
evaluations of the thoracic spinal cords were performed on all of these dogs.  
Only those dogs that had exhibited clear clinical signs of DM, and thoracic spinal 
cord lesions characteristic of this disease (Averill 1973) were designated as DM-
affected.  Control tissue was obtained from age and breed matched unaffected 
dogs euthanized for causes unrelated to DM.  Dogs were designated as controls 
if they had not exhibited clinical signs of DM and histological appearance of the 
thoracic spinal cord tissue was normal.  Dogs that exhibited clinical signs similar 
to those of DM were excluded if their clinical signs were associated with spinal 
cord compressive lesions detected by magnetic resonance imaging or 
myelography or if the thoracic spinal cord histopathology was not typical for a 
diagnosis of DM [(Coates and Wininger 2010).   
Genotypes at canine SOD1:c.118G>A were determined for each dog 
included in the study using a TaqManTM allelic discrimination assay that 
employed  5’-GTGGGCCTGTTGTGGTATCA-3’ with 5’-
CAAACTGATGGACGTGGAATCC-3’ for the PCR primers and 5’-VIC-
CTCGCCTTTAGTCAGC-MGB-3’ (A allele) and 5’-FAM-CGCCTTCAGTCAGC-
MCB-3’ (G allele) for the completing probes (Awano et al. 2009). The 
classification of the dogs by disease status and genotype is shown in Table 5 
55 
 
When an owner elected to have a dog euthanized, the veterinarian who 
would perform the necropsy was provided with a kit that included detailed 
instructions and materials for sample collection, preservation and shipping.  
Detailed clinical histories were obtained to document the age at onset and 
progression of clinical signs, neurologic status at the time of euthanasia, and any 
unrelated health problems. Necropsies were performed within 6 hours after 
euthanasia.  Protocols for tissue collection were approved by the University of 
Missouri Animal Care and Use Committee. Tissues collected included thoracic 
spinal cord segment 6 (T6) fixed in buffered 10% formalin, the T7 segment fixed 
in 3.5% paraformaldehyde with 0.1% glutaraldehyde and 120 mM sodium 
cacodylate, 1 mM CaCl2, pH 7.4 (Immuno-fixed), and the T8 segment (with 
ventral and dorsal roots, and dorsal root ganglion intact) fixed in 2% 
glutaraldehyde, 1.12% paraformaldehyde, 130 mM sodium cacodylate, 1 mM 
CaCl2, pH 7.4 (electron microscopy [EM]-fix).  Blood samples for DNA isolation 
were collected in EDTA vacutainer tubes (Becton Dickenson, catalogue 
#367899). 
Disease status determinations 
Confirmation of disease status for each dog was performed as previously 
described( see chapter 2). Briefly, disease stages at time of euthanasia were 
determined using a clinical grading scale (Table 2. Clinical grading scale of 
disease progression in DM-affected dogs) (Shelton et al. 2012). DM diagnoses 
were confirmed histopathologically by assessing the T6 cord segment for 
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evidence of myelinated axon loss and pronounced astrogliosis in the dorsal the 
typical histopathology were presumed to have another cause for the myelopathy 
and excluded from the study.  T7 spinal cord segments were examined for the 
presence of SOD1 immunoreactive aggregates within ventral portion of the 
lateral funiculus (Averill 1973; March et al. 2009). Dogs that had exhibited clinical 
signs  of DM but did not show horn motor neurons (Awano et al. 2009). Dogs that 
had not exhibited any clinical signs of DM prior to euthanasia and whose thoracic 
spinal cords were histologically normal were used as controls.  Tables 4 and 5 
provide a summary of the disease status of the dogs employed in this study. 
 
Table 4. Summary of the number of dogs within each disease grade 
 Numbers of dogs in each grade 
Breed Control Grade 1 Grade 2 Grade 3 Grade 4 
PWC 7  0 5  4  6  
Boxer 6  3  3  2  1  
 *See Table 2 for definitions of disease grades 
 
Table 5. SOD1 genotypes 
Number of Dogs of Each SOD1 Genotype (age in 
years) 
Disease Status & 
Breed 
G/G A/G A/A 
Unaffected PWC 1 (16yrs) 4 (13-17yrs) 2 (13-14yrs) 
Affected PWC 0 0 15 (12-15yrs) 
Unaffected Boxer 0 4 (8-12 yrs) 2 (9yrs) 
Affected Boxer 0 0 9 (10-12 yrs) 
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Spinal cord motor neuron cell body counts 
An immuno-fixed T7 spinal cord segment from each dog was embedded in 
paraffin.  From each paraffin-embedded sample, 4µm sections (each separated 
by at least 100μm) were placed on positive charged slides (1 section per slide), 
and left flat on a 430C slide warmer overnight. The slide-mounted sections were 
steam-treated in a decloaking chamber (Biocare Medical, Concord,CA.)  at 980C 
for 30 minutes in citrate target retrieval solution (Dako, Carpinteria, CA.), cooled 
at room temperature for 10 minutes, rinsed with distilled water, then placed on 
IntelliPATH FLX autostainer for staining. Slides were treated with 3% H202 for 15 
minutes, washed in buffer, treated with Sniper block (Biocare Medical, Concord, 
CA.) for 20 minutes. They were then incubated in primary antibody goat anti-
choline acetyl transferase (ChAT) (Millipore AB144P;1:200) for 60 minutes. 
Control sections were treated with nonimmune rabbit IgG (Sigma, St. Louis, MO.) 
at a 1:1000 dilution for 60 minutes in place of the anti-ChAT antibody.  The 
detection system used was rabbit anti-goat horse radish peroxidase (HRP) kit 
(PK6105;Biocare Medical, Concord, CA.) with 30 minute incubations in link and 
label steps followed by a tris buffer rinse. The sections were then incubated in 
romulin red (Biocare Medical, Concord, CA.) for 10 minutes.  Slides were 
counterstained in hematoxylin (Biocare Medical, Concord CA.) at a 1:10 dilution 
for 5 minutes then followed with a tris-buffered rinse, dehydrated, coverslipped, 
and then imaged with light microscopy at 200x magnification. The numbers of 
ChAT-positive cell bodies in Rexed lamina 9 per section were determined by 
counting the cells in a sufficient number of sections from each spinal cord sample 
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such that a minimum of 100 cells per dog were counted.  Using Image J™ 
software, cross-sectional area (CSA) was determined for all ChAT-positive cells 
in Rexed lamina 9. CSA and diameter of motor neurons with visible nucleoli were 
also determined 
Morphometric and pathologic analyses of nerve roots  
Approximately 3 mm long segments of ventral and dorsal roots were 
dissected from the EM-fixed T8 cord segments.  The samples were post-fixed 
with 2% osmium tetroxide and subjected to extended microwave infiltration and 
embedded in epon araldite resin. After resin embedding, blocks were 
polymerized at 60˚C for 48 hours, and nerve cross-sections were cut at a 
thickness of 0.4µm. The sections were stained in 2% P-phenylene diamine (PPD) 
solution (MP Biomedicals, LLC, catalog # 151830) (1g PPD in 50ml of 50% 
EtOH) made up 5 days  to 2 weeks prior to use.  Sections were incubated in 
filtered PPD solution for 15 minutes, rinsed 1-3 times in ultra-pure H2O, covered 
with Permount mounting medium and coverslipped.  High resolution images of 
each stained nerve cross section were obtained using a Leica DMI 6000B 
inverted scope equipped with a programmed stage and Leica application suite 
advanced fluorescence software™ (LAS-AF).  Using automated stage controls 
and image acquisition individual images totaling the entire area of each section 
were obtained using a 40X objective and stitched together by the LAS-AF 
software to create a single high-resolution image of the tissue cross section.  The 
sharpness and contrast of the composite images were optimized using 
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Photoshop™ software.  The resulting images were then analyzed using 
MetaMorph® image analysis software to obtain the following morphometric data 
for each nerve: total myelinated axon number, endoneurial area, endoneurial 
area occupied by axons, percent axon occupancy (percentage of endoneurial 
space occupied by myelinated axons), axon density, and axon size distribution.  
The image analysis procedure is summarized in figure. 11.PPD and toluidine 
blue stained sections of the motor roots were examined for histopathogical 
abnormalities by an experienced pathologist (GDS) in a masked manner. Fibers 
with inappropriately thin myelin sheaths relative to axon diameter, myelin splitting 
and ballooning, axonal degeneration and number of probable regenerating 
clusters (defined as two or more closely apposed myelinated fibers) were 
assessed in each nerve specimen. As previously described (Shelton et al. 2012), 
only those fibers with clear, faintly staining space evident between separated 
myelin with an asymmetrical profile are considered to have splitting and 
ballooning, while profiles containing paranodal regions or Schmidt-Lanterman 
clefts were not counted 
Statistical analyses 
Data for each breed was evaluated independently.  Each data set was 
evaluated for normality using the Shapiro-Wilk normality test. For data that were 
60 
 
.  
Figure 11. Procedure for obtaining morphometric measurements in T8 
motor and sensory root cross sections. (A) Resin embedded nerves were 
sectioned and stained with P-phenylene diamine (PPD), imaged using light 
microscopy, and composite images of the entire nerve cross-sections were 
constructed. (B) Magnified image of area outlined in (A). (C) Images were 
sharpened using Photoshop™ tools. (D) Imaris® software was used to invert the 
image, and remove background noise. (E) Multicolored image produced by the 
automated count tool in MetaMorph® software. Colors indicate what software 
distinguishes as individual objects. Note that several adjacent axons are being 
mistaken for a single object. (F) Manual corrections were made in Photoshop by 
overlaying, and increasing the transparency of, the multicolored image over the 
sharpened light micrograph.  (G) Multicolored images after manual corrections. 
(H) Corrected multicolored image of entire nerve root cross-section. (Illustration 
represents a T8 motor root cross section). 
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normally distributed Student’s t-test was employed to determine whether 
significant changes exist between affected and unaffected groups. When data 
were analyzed using disease stage (early and late) as a variable, data were 
subjected to analysis of variance followed by Holm-Sidak analyses to compare 
individual groups.  Data that were not normally distributed were analyzed using 
the Mann-Whitney ranked sum test 
Results 
T7 motor neuron density and morphology 
DM did not result in significant changes in mean motor neuron densities or 
mean cell body cross-sectional areas of the T7 spinal cord segment for either 
breed compared to controls, even when data for all affected dogs within each 
breed were pooled (Figure 12.C), or when control samples were compared only 
to late stage DM samples (data not shown). In some affected and unaffected 
samples of both breeds motor neuron morphological abnormalities (i.e. vacuoles, 
eccentric nuclei, and shrinkage) were occasionally seen, with no apparent 
association with disease status (Figure 12. B). 
No disease related changes were seen in ventral root motor axons 
Among Boxers and PWCs, DM was not associated with significant 
alterations in the motor root features that were analyzed relative to age matched 
unaffected dogs, even in dogs in the most advanced stages of clinical disease 
(Tables 6 and 7). Total numbers of axons in the motor roots were similar 
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Figure 12. Thoracic motor neuron morphometric measurements. (A, B) T7 
spinal cord section from an unaffected 9 year old Boxer stained with ChAT. (B). 
Higher magnification of highlighted box within Rexed lamina 9 in A.  This image 
is a representation of the normal motor neuron morphology seen in unaffected 
and affected dogs of both breeds. (C) Morphometric measurements obtained 
from PWC (top) and Boxers (Bottom).  Pooled data indicate no difference in the 
motor neuron density between unaffected and affected samples of either breed 
(Affected boxers: one grade 1, three grade 2, one grade 3, and two grade 4 
dogs; Affected PWC: two grade 2, two grade 3, and four grade 4 dogs). Likewise 
no differences were seen in the mean soma cross sectional area (CSA) or size 
range. In PWC’s a significant difference was seen in the CSA standard deviation, 
suggesting more variability in soma area in affected dogs (p=0.02). One Way 
ANOVA indicated the difference in standard deviation is attributed to a significant 
difference between unaffected and late stage (grade 3-4) PWC samples (p= 
0.04). 
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between affected and normal dogs within each breed.  Among both normal and 
affected dogs, the Boxers consistently had larger numbers of axons in the 
thoracic motor roots than did the PWCs (Tables 6 and 7).  Additionally, when 
data were separated into early and late stage groups within each breed, no 
significant differences were detected in any morphometric measurements 
compared to control unaffected motor roots (data not shown). Size distribution 
histograms reveal a bimodal distribution of axon diameters typical of thoracic 
ventral roots (Figure 12). The smaller caliber peak (≤ 5 microns) represents 
axons of autonomic neurons from the intermediolateral horn (Sobue et al. 1981). 
The larger caliber peak (>5 microns) likely represents alpha motor axons (Braund 
et al. 1982a). There were no differences in the relative distribution of axons 
Table 6. PWC T8 motor root morphometric measurement results 
PWC T8 Motor Roots Unaffected Affected P value 
Number of dogs 5 8  
Average count of axons 3,676 ± 262 3,863 ± 691 0.57 
Average endoneural CSA  
(µm
2
) 
308,081.54 ± 
39,460.49 
297,826.80 ±  
55,818.72 
0.72 
Average area occupied by 
axons (µm
2
) 
191,114.56 ± 
35,453 
179,168.71 ± 
24,679.03 
0.48 
% of endoneural area 
occupied by axons 
61.7% ±  6.1% 60.7  ±  5.8% 0.78 
Average axon density 
count/mm
2
) 
12,165.08  ± 
2,131 
13,400.49 ± 
3,874.93 
0.53 
* 5 unaffected and 8 affected (four grade 2, one grade 3, and three grade 4) dogs 
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Table 7. Boxer T8 motor root morphometric measurement results 
Boxer T8 Motor Roots Unaffected Affected P value 
Number of dogs 5 8  
Average count of axons 4,697 ± 827 4,140 ± 1,104 0.35 
Average endoneural 
CSA  (µm
2
) 
443,654.10 ± 
94,990.21 
464,871.30 ± 
124,963.56 
0.75 
Average area occupied 
by axons (µm
2
) 
267,532.55 ± 
69,695.82 
269,769.55 ± 
62814.24 
0.95 
% of endoneural area 
occupied by axons 
60.3 % ± 8.5% 59.1% ± 9.8% 0.83 
Average axon density 
(count/mm
2
) 
10,850.21 ± 
2,368.04 
9,039.09 ± 2,143.59 0.22 
*5 unaffected and 8 affected (two grade 1, three grade 2, one grade 3, and two grade 4) 
dogs 
between these two size classes between samples from unaffected and affected 
dogs (Figure 13).  Histopathologic changes including myelin pathology, axonal 
degeneration, and presumptive regenerative clusters were present in control and 
affected samples from both breeds (Table. 8). Since no apparent association with 
disease was noted, these changes likely represent features of normal aging or 
may also include postmortem artifacts. 
Significant axonal loss in T7 dorsal roots of DM-affected Pembroke Welsh Corgis  
Late stage DM (grades 3 and 4) was accompanied by an average 23% reduction 
in the number of T7 dorsal root axons of PWC’s (unaffected: 3,261 ± 354, 
affected: 2,498 ± 324, p = 0.003) (Figure 14 and 15); however, no differences 
were seen in the other morphometric measurements including average 
C
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Table 8. Histopathological assessment motor root myelinated axons 
Grade Breed 
Splitting, ballooning, 
and myelin thickness 
Axonal 
degeneration 
Regenerative 
clusters 
0 Boxer ++, numerous thin ++ possible 
0 Boxer 
+, splitting, thin, 
regional 
0 possible rare 
0 Boxer +++ thin ++ possible yes 
0 Boxer ++, numerous thin + few 
0 Boxer 0 0 0 
1.5 Boxer numerous thin ++  possible yes 
1.5 Boxer numerous thin ++ possible yes 
2 Boxer numerous thin + few 
2 Boxer few split, few thin 0- + 0 
2.5 Boxer few split, few thin 0- + few 
3 Boxer few split, + thin 0 0 
4 Boxer numerous thin 0 possible yes 
4 Boxer several thin, regional 0 few 
0 PWC few thin 0 few 
0 PWC ++, numerous thin ++ possible yes 
0 PWC rare thin 0 few 
0 PWC ++, numerous thin 0 few 
0 PWC +,moderate thin +++ few 
2 PWC +, numerous thin 0 few 
2 PWC +, numerous thin 0 possible yes 
2 PWC + 0 uninterruptable 
2 PWC +,++ + 0 
4 PWC +,++ 0 0 
* Mild pathology = +. Moderate = ++, Severe = +++ 
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endoneurial cross sectional area, average area occupied by axons, % of 
endoneurial area occupied by axons, and average axon density (Table 9 ). The 
axons in the sensory roots also exhibited a bimodal distribution in axon diameters 
(Figure 15). The disease-related decrease in axon number in sensory roots was 
seen in both large (>5µm) and small (≤ 5 µm) size classes (Figure 15). 
Morphological features indicative of myelin pathology and axonal degeneration 
were not disease-associated (Table 10). Among the affected PWCs, the dorsal 
root ganglia (GRGs) had large numbers of cells with dark condensed cytoplasm 
and pyknotic nuclei (Fig. 14D) which were not seen in DRGs from age-matched 
unaffected dogs (Fig.1 4C).  
Discussion/Conclusion  
Despite substantial atrophic changes that occur in the intercostal muscles 
in late stage DM (Morgan et al. 2013), no alterations in the numbers of thoracic 
lower motor neurons nor their axons were observed in dogs with this disorder. 
Likewise, we previously reported that there was no evidence of denervation of 
the intercostal muscle acetyl choline receptors in DM (Morgan et al. 2013), unlike 
Figure 13. Motor root myelinated axon diameter distribution from PWC's 
and Boxers. Motor root myelinated axon diameter distribution from PWC’s (A,B) 
and Boxers (C,D). Histograms show a bimodal size distribution with one peak 
representing small caliber axons, and one peak representing large caliber axons 
(A, C). For both breeds, no obvious differences could be seen between large 
caliber axons from control and affected motor roots, while the small caliber peak 
was more variable. (B, D) For both breeds, no statistical difference was seen in 
the percentage or average numbers of axons ≤5 µm >. Data represented in this 
figure were obtained from the same samples depicted in tables 6 and 7. 
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 the denervation reported in some putative mouse models of ALS (Dadon-
Nachum et al. 2011; Fischer et al. 2004; Schaefer et al. 2005). These data 
indicate that intercostal muscle atrophy in DM is not secondary to loss of physical 
contact with motor neurons, yet may be secondary to functional defects in the 
motor neurons that are not reflected in obvious structural changes in the nerves. 
In a recent study by Ogawa et al. that included Japanese DM-affected PWCs 
exhibiting respiratory signs, loss of thoracic motor neurons was observed  
 
 
 
Figure 14. PWC sensory root and dorsal root ganglia histopathology. 
Histological sections of T8 sensory roots (A and B) and dorsal root ganglia 
(DRG) (C and D) in PWC samples. EM-fixed sensory roots and DRG from control 
(A,C) and grade 4 (B,D) PWC samples were embedded in resin and stained with 
PPD and toludine blue respectively. Compared to controls (A), sensory roots 
from grade 4 PWC (B) exhibited decreased myelinated axon density. DRG 
neurons from grade 4 PWC (D) contained numerous cells with condensed 
cytoplasm (arrowhead) and severely pycnotic nuclei (arrow) that were not 
present in the DRG neruons from age-matched control dogs (arrowhead and 
arrow in C denote cytoplasm and nucleus of normal neuron for comparison). 
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Table 9. PWC morphometric sensory root data 
PWC T8 
Sensory Roots 
Unaffected Affected P value 
number of dogs 6 6  
Average count of 
axons 
3,261 ± 354 2,498 ± 324 0.003* 
Average endoneural 
CSA  (µm
2
) 
299,035.80 ± 
51,135.46 
287,306.10 ±  
104,376.02 
0.81 
Average area occupied 
by axons (µm
2
) 
168,275.15 ± 
50,113.15 
131,682.17 ± 
28,538.90 
0.15 
% of endoneural area 
occupied by axons 
56.9% ± 15.1% 48.2 ± 9.5% 0.26 
Average axon density 
(count/mm
2
) 
11,078.84 ± 
1,663.80 
9,606.45 ± 
3,192.25 
0.34 
*affected samples:  two grade 3, four grade 4 
(Ogawa et al. 2013). In Japan, DM- affected dogs are often maintained even 
after the onset of respiratory distress (Ogawa et al. 2011; Ogawa et al. 2013), 
while in other countries dogs with DM are usually euthanized when they become 
nonambulatory in the pelvic limbs (Coates and Wininger 2010). Based on a 
comparison of our findings with those from the study of the PWCs from Japan, it 
appears that motor neuron loss may be a feature of DM that only becomes 
apparent in the terminal stage of disease.  
In late stage DM intercostal muscles display a marked increase in type-1 
myofibers(Chapter 2), similar to that observed in a SOD1 transgenic mouse 
model with a low copy number of the mutant allele (Acevedo-Arozena et al. 
2011). Because myosin isoform expression is dictated by the motor neuron 
(Buller et al. 1960), this change suggests pathology within the motor neuron. DM  
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thoracic motor neurons contain accumulations of insoluble SOD1-containing 
 cytoplasmic aggregates, which increase over disease duration (Crisp et al. 
2013) (Awano et al. 2009). Moreover, Ogawa et. al., showed that astrocytes in 
thoracic and cervical gray matter have reduced expression of glutamate 
transporter 1 (GLT-1) (Ogawa et al. 2013), and increased iNOS labeling (Ogawa 
et al. 2011) which may contribute to dysfunction of the associated motor neurons. 
Therefore, rather than analyzing the physical preservation of the motor unit 
Figure 15. PWC sensory root myelinated axon diameter distribution. 
(A)Histogram shows a bimodal size distribution with one peak representing small 
caliber axons, and one peak representing large caliber axons. (B) There was a 
statistically significant difference in the average number of axons ≤5 µm (p= 0.03) 
and >5 µm (p=0.03). Data represented in this figure were obtained from the same 
samples depicted in table 9  
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structures, future studies should be targeted to obtain a better understanding of 
Table 10. Histopathological assessment sensory root myelinated axons 
Grade Breed 
Splitting, ballooning, 
and myelin thickness 
Axonal 
degeneration 
Regenerative 
clusters 
0 PWC + thin + ++ sprouts 
0 PWC + thin, demyelinated, 
partially myelinated 0 0 
0 PWC ++ split, ballooning  0 0 (aging?) 
0 PWC + split, ++ thin + 0 
0 PWC + split, ++ thin + 0 
0 PWC + ballooning, ++ thin 0 0 
2 PWC ++ thin 0 +++ possible  
3 PWC + thin 0 0 
3 PWC + thin 0 0 
4 PWC rare split, ballooning  0 0 
4 PWC + thin, + ballooning  0 0 
4 PWC +++ thin 0 0 
4 PWC + thin, ballooning 0 0 
* Mild pathology = +. Moderate = ++, Severe = +++ 
the molecular dysfunction within spinal motor neurons and non-neural supporting 
cells of DM dogs.  
This study was consistent with a previous suggestion that DM dogs 
exhibited severe degeneration in lumbar sensory roots and minor chromatolysis 
in DRG, with relative sparing of lumbar motor roots report (Griffiths and Duncan, 
1975).  Although clinical signs of DM and ALS are primarily associated with 
motor dysfunction, sensory deficits also are known to occur as part of the clinical 
spectrum of both diseases (Andersen et al. 1996; Andersen et al. 1995; Averill 
1973; Coates and Wininger 2010); (Dyck et al. 1975; Isaacs et al. 2007; Mulder 
et al. 1983; Pugdahl et al. 2007). For example, sensory symptoms in patients 
with ALS have been reported to include numbness in the legs and a burning 
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sensation in the feet, decreased light touch and pinprick sensation, reduced 
vibration sense, and reduced laryngeal sensation.   Additionally, sensory fiber 
loss has been reported in sural nerves (di Trapani et al. 1986; Giannini et al. 
2010; Heads et al. 1991; Isaacs et al. 2007), and dorsal roots (Kawamura et al. 
1981) in familial and sporadic ALS patients and in transgenic SOD1 rodent 
models (Guo et al. 2009). Within the disease spectrum of ALS, cases with 
sensory involvement may represent a variant of the disease or a continuum of 
the multisystemic neurodegeneration (Heads et al. 1991). Degenerative 
myelopathy may serve as a disease model for a subset of ALS patients.  Our 
data indicating that significant loss of sensory neurons precedes any physical 
loss of motor neurons in the thoracic spinal cord suggests that more thorough 
investigation of the potential role of sensory pathology in ALS is warranted. 
Every dog in which DM has been confirmed, both on the basis of clinical 
signs and the presence of characteristic pathological lesions in the thoracic 
spinal cord, has been homozygous for the SOD1:c.118G>A mutation, so there is 
little doubt that this mutation is closely associated with the disease.  However, 
among the PWCs examined in this study, affected dogs were euthanized as a 
consequence of the disease as early as 12 years of age, whereas two of the 
seven unaffected PWCs were homozygous for this mutation and had not 
exhibited any of the clinical signs of DM or any spinal cord pathology by 13 to14 
years of age.  This indicates that there are other factors that determine whether a 
genetically predisposed dog develops DM or at least the age at which the 
disease develops.  An understanding of the factors that modify the age of onset 
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and rate of disease progression in DM may be useful in developing effective 
treatments for ALS. 
DM as a disease model may serve as a valuable tool to investigate 
disease mechanisms, therapeutic strategies and disease markers for ALS. It is 
important to continue to thoroughly characterize DM, and develop outcome 
measures to provide biomarkers for reliable assessments of the efficacy of 
potential therapeutic interventions  
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CHAPTER 4 
 General Discussion 
In this study, we have shown that intercostal muscle atrophy occurs in late 
stage DM without physical evidence of MN or motor axon degeneration. Also 
there was no loss of physical synaptic connectivity with nicotinic acetylcholine 
muscle receptor complexes. Although the MN soma appeared to be physically 
intact, the pattern of muscle pathology was consistent with defects in neuronal 
input. For example, intercostal myofiber variability seen in grade 4 samples was 
consistent with denervation atrophy, suggesting primary dysfunction within the 
MN. The change observed in fiber type distribution in grade 4 PWC samples may 
have also been indicative of changes in neuronal input. 
Intercostal muscle pathology seen in this study had several similarities 
and difference compared to that seen in hind limb muscle of DM affected dogs. 
Early stage Boxer intercostal and hind limb muscles had minimal pathologic 
changes, while late stage Boxer hind limb muscle revealed extensive fiber typed 
grouping and marked myofiber size variability (Shelton et al. 2012). 
Unfortunately, because Boxers were generally euthanized at earlier disease 
grades, late stage intercostal muscle available for the current study was limited. 
Therefore it is unknown whether intercostal muscle pathology correlated with that 
seen in hind limb muscle in DM affected Boxers.  Grade 4 PWC hind limb muscle 
histopathology did not exhibit fiber type grouping and had an appearance which 
resembled a mixture of denervation and accelerated sarcopenia (Shelton et al. 
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2012), differing from the denervation atrophy and fiber type distribution  changes 
observed in this study. These results indicate that disease related 
histopathological changes may differ between breeds and MUs (i.e. thoracic MU 
vs. lumbar MU). 
The increase in type 1 myofiber predominance could have been from 
substantial fiber-typed grouping, in which a large portion of myofibers were 
reinnervated with neurons dictating a type 1 phenotype. Type 1 myofibers have 
been shown to be more resistant to the ALS disease process than type 2 and/or 
axons innervating type 1 fibers have a better capacity to sprout in response to 
disease (Acevedo-Arozena et al. 2011; Frey et al. 2000; Hegedus et al. 2007; 
Schaefer et al. 2005). In 1994, Gurney et. al. reported that distal axonal sprouting 
likely compensated for muscle death until late in the disease course in the SOD1 
G93A mouse (Gurney et al. 1994). In a muscle displaying scarcely denervated 
endplates, 90% of myofibers in the gluteus muscle were innervated by two 
surviving axons of the inferior gluteal nerve (Gurney et al. 1994). In low copy 
number SOD1 G93A mice, Acevedo-Arozena  et. al. also reported substantial 
increases in type 1 myofibers of the extensor digitorum longus muscle, 
suggested by the authors to be a result of fiber-typed grouping (Acevedo-
Arozena et al. 2011). Therefore reinnervation by axonal sprouts from neurons 
dictating a type 1 myofiber phenotype could explain the lack of denervated 
muscle receptors and the increase in type 1 myofibers observed in grade 4 PWC 
intercostal muscles. 
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Alternatively, because we did not observe any loss of or alterations in 
diameter distributions of myelinated axons, MU structures may have lost 
functional synaptic connections. Studies in transgenic mutant SOD1 mice, 
utilizing inhibition of apoptosis (Dewil et al. 2007; Gould et al. 2006) or 
administration of histone deacetylase inhibitors (Rouaux et al. 2007), showed 
that MN death is dissociated from motor dysfunction. In these studies, MN somas 
and proximal axons were protected from degeneration; however, progressive 
functional decline persisted. Similar results were reported in which preservation 
of MUs, including neuromuscular junctions, occurred in transgenic mouse models 
for SOD1-ALS and Charcot-Marie-Tooth disease 2E (Lobsiger et al. 2005; Shen 
et al. 2011). In these reports, preservation of MU structures also did not prevent 
functional decline. MU function may also be compromised by alterations in 
synaptic input from cortical and brain stem neurons (Sasaki and Maruyama 1994; 
Sunico et al. 2011). MN and motor root axon loss were recently reported in 
terminal DM affected PWC displaying respiratory impairment (Ogawa et al. 
2013).Therefore, it was possible that physical loss of MU structures only 
occurred  in terminal DM disease stages; however, functional deficiency 
preceded physical loss.  
Muscle atrophy associated with SOD1 mutations may be partially due to 
direct effects of the mutations on the muscle rather than secondary to alterations 
in MN input (Marcuzzo et al. 2011; Wong and Martin 2010; Zhou et al. 2010). 
Supporting this concept, restricted expression of mutant SOD1 within muscle of 
transgenic mice was sufficient to generate a MN disease phenotype comparable 
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to ALS (Wong and Martin 2010). In a similar study Dobrowolny and colleagues 
demonstrated that myofiber restricted mutant SOD1 expression in transgenic 
mice was sufficient to cause severe muscle atrophy, decreased muscle strength, 
and sarcomere and sarcotubuloar disorganization (Dobrowolny et al. 2008). 
These authors also reported an alteration in mitochondrial distribution associated 
with a shift in myofiber metabolism from glycolytic to oxidative in hind limb 
muscle(Dobrowolny et al. 2008). In primary LMN diseases such as spinal and 
bulbar muscular atrophy (SBMA), histological features consistent with myopathic 
diseases have been identified (Onesto et al. 2011). For example, In addition to 
characteristic neurogenic atrophy, skeletal muscle pathology in patients and 
mouse models with SBMA also revealed features of primary muscle disease 
including splitting and necrotic fibers (Amato et al. 1993; Harding et al. 1982; 
Mariotti et al. 2000; Sobue et al. 1989; Soraru et al. 2008b). Therefore the 
muscle pathology observed in this study could partially be associated with 
primary abnormalities within myofibers.  
 Results from this study indicated significant pathology within DRG neurons 
and sensory root axons. In the initial description of DM, Griffiths and Duncan 
reported histopathologic changes in these sensory structures in lumbar spinal 
regions (Griffiths and Duncan 1975).  Sensory root axons displayed evidence of 
degeneration and DRG neurons exhibited features of cell death, with relative 
sparing of lumbar motor roots and MNs (Griffiths and Duncan 1975).  The 
present study complimented these findings with more detailed methodology and 
emphasized the significant impact of DM on sensory pathways.  A reduction in 
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DRG neurons and sensory root axons from the L5 spinal segment in ALS 
patients has been reported (Kawamura et al. 1981).  Similar results were also 
seen in the SOD1 G93A mouse with progressive dorsal root axon loss and DRG 
degeneration (Guo et al. 2009). The function of MNs innervating intercostal 
muscles was partially dependent on a feedback loop that involved the sensory 
neurons from the same cord segment.  It was possible that the pathology 
exhibited by thoracic sensory neurons resulted in secondary abnormal function of 
the MNs they innervated, and consequently was involved in the intercostal 
muscle atrophy observed (Ausborn et al. 2009; Mentis et al. 2011).  
 The purpose of this study was to further characterize DM through MU 
analysis. However, on a broader scope our goal was to assist in establishing 
whether DM could serve as a reliable ALS disease model. In addition to what has 
already been described in DM, the results from this study suggested that DM is a 
good disease model for some forms of ALS. DM is mainly a recessively inherited, 
disease associated with mutations in SOD1 (Awano et al. 2009).  There was 
disruption of motor and sensory pathways initiating in the lower limbs (Averill 
1973; Griffiths and Duncan 1975). Disease progression was very stereotyped 
and predictable (see Table 11)(Coates and Wininger 2010). Although the fate of 
the majority of ALS patients is the same (i.e. muscle paralysis, and premature 
death), the disease progression and onset is heterogeneous; therefore, not all 
forms of ALS can be compared to canine DM. However, SOD1 D90A was one form 
of ALS that shared many of these characteristics with DM (Table.11) (Andersen 
et al. 1996; Andersen et al. 1995). ALS is a devastating disease and there are no 
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effective treatments for any form of ALS. Because DM resembles the recessive 
SOD1 D90A form of ALS, we believe that it will serve as a disease model in our 
ultimate goal of developing treatments for ALS patients and DM affected dogs. 
Compared to transgenic mutant SOD1 mice, DM affected dogs in this 
study were not genetically altered and had a naturally occurring mutation in the 
SOD1 gene (Table. 11) (Awano et al. 2009). Because the SOD1 mutation was 
not overexpressed, as with the most commonly used transgenic mutant SOD1 
mouse model (Gurney et al. 1994), the disease progression in DM affected dogs 
was more comparable to human ALS (Coates and Wininger 2010). Another 
important defining feature of DM affected dogs was that these companion 
animals shared the same environment as humans, and some environmental 
factors have been considered risk factors for ALS development (Ahmed and 
Wicklund 2011; Fang et al. 2010; Garruto et al. 1989; Roelofs-Iverson et al. 
1984; Spencer et al. 1986). While our knowledge about the pathogenic 
mechanisms of ALS was derived from transgenic rodent studies, there is growing 
concern about the preclinical application of these rodents in ALS (Benatar 2007; 
Gordon and Meininger 2011). Canine DM as another tool will serve as a suitable 
bridge for this translational gap. 
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Table 11. Comparative summary of human ALS and ALS disease models 
 Genetics 
Clinical 
onset 
Disease 
progression 
Disease 
Duration 
Motor Unit 
histopathology 
Sensory 
defects 
Bladder 
dysfunction 
ALS  
(all forms) 
 90% sporadic variable variable variable 
 MN loss 
 motor axon loss 
 neurogenic atrophy 
 fiber typed grouping in 
some forms 
yes, rare no 
SOD1 FALS 
 2% of all ALS 
 >160 mutations 
 Mostly dominant 
variable variable variable 
 MN loss 
 motor axon loss 
 neurogenic atrophy 
 fiber typed grouping 
yes no 
SOD1-D90A 
human 
FALS 
 recessive and 
dominant 
stereotyped stereotyped protracted 
 MN loss 
 motor axon loss?? 
 neurogenic atrophy 
 fiber typed grouping 
yes yes 
High copy # 
transgenic 
G93A SOD1 
mice 
 overexpression of 
SOD1 mutation  
stereotyped stereotyped rapid 
 significant MN death 
late  
 NMJ disruption early 
 neurogenic atrophy 
 fiber typed grouping  
 dying back pathology 
yes no 
SOD1 
canine DM  
 naturally 
occurring 
mutation 
 mostly recessive 
stereotyped stereotyped protracted 
 MN and motor axon 
death in terminal stages 
  no NMJ disruption 
 neurogenic atrophy 
 fiber typed grouping?? 
yes yes 
*High copy number SOD1 G93A transgenic mouse is the most commonly used model in ALS preclinical studies 
D90A SOD1 FALS 
?? Undetermined 
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CHAPTER 5 
Future Directions 
The work conducted in this study contributed to the understanding of 
canine DM by broadening our general knowledge of the MU pathology involved 
in the DM disease progression. Additionally, results from this investigation have 
laid a foundation for future studies that are needed to further characterize canine 
DM. 
As mentioned previously, MN and motor axon loss in DM may be features 
of terminal disease stage in the mid thoracic spinal cord. It is unlikely that we 
would be able to characterize MUs at terminal disease stages in this country due 
to animal welfare concerns. However analyzing MUs from other spinal cord 
segments could give us a more complete picture of the temporal degeneration of 
other MUs in DM. Ravits et. al. reported that in human ALS patients MN loss is 
focally more severe at the site of clinical onset (Ravits et al. 2007). Clinical signs 
begin in the pelvic limbs and later progress to involve the thoracic limbs and 
bulbar functions in DM-affected dogs (Awano et al. 2009; Coates and Wininger 
2010). Therefore, within the same dog it is possible for us to evaluate MUs at 
various time points in the degenerative process. In future studies, morphometric 
methods, similar to the ones used in the present study, could be applied on 
spinal cord segments collected from the lumbar and cervical intumescences and 
brain stem motor nuclei.  
Along with our finding of denervation atrophy in DM-affected PWC 
 82 
 
intercostal muscles, respiratory dysfunction in DM was a novel finding (Ogawa et 
al. 2011; Ogawa et al. 2013). DM-affected PWCs in Japan have been reported to 
display clinical evidence of respiratory muscle impairment at terminal disease 
stages (Ogawa et al. 2011; Ogawa et al. 2013). In those studies, clinical 
evaluations of these dogs were not extensively described (Ogawa et al. 2011; 
Ogawa et al. 2013). Because ALS patients die as a result of weakness and 
paralysis of respiratory muscles, including the intercostal muscles (de Carvalho 
et al. 2010), it will be important to further investigate the possibility that DM would 
Figure 16. Tidal breathing flow-volume loop. Loops are plotted as volume 
(mL) vs  flow (L/sec). Normal loops resemble a “D” shape. Inspiration begins on 
the right side and continues clockwise as inspiration ends, and expiration begins 
(arrows). Changes in loop shape may be indicative of respiratory abnormalities.  
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give rise to the same fate in dogs. Therefore further studies should be conducted 
to evaluate the onset and early progression of respiratory muscle abnormalities 
in DM-affected dogs.  
Pulmonary function testing is regularly used as a biomarker in the ALS 
field to monitor the progression of respiratory deficiencies (Brinkmann et al. 1997; 
Czaplinski et al. 2006). Common methods employed in human medicine require 
voluntary patient cooperation. For instance forced vital capacity (FVC) evaluates 
the amount of air a patient can move out of the thoracic cavity in a forced 
maneuver(Brinkmann et al. 1997; Czaplinski et al. 2006). Because dogs are not 
able to comply with such requests, pulmonary function techniques have been 
adapted for use in small animals. One example is the assessment of tidal 
breathing flow-volume loops (TBFVL) (Figure 16), which quantitatively measures 
airflow patterns at rest (Rozanski and Hoffman 1999). In an awake animal, a 
tight-fitting mask with a pneumotachograph (apparatus for recording rate of air 
flow) is placed over the muzzle. Loops are then plotted as volume (mL), and flow 
(L/sec) on the x, and y axis respectively (Miller 2007; Rozanski and Hoffman 
1999).  Normal loop appearance resembles a “D” (see figure above). Inspiration 
begins on the right hand side and the loop continues clockwise as inspiration 
ends, and expiration begins (Rozanski and Hoffman 1999). Calculated loop 
indices (i.e. tidal volume [mL], inspiratory time [msec], expiratory time, peak 
inspiratory flow [mL/sec], peak expiratory flow, etc) have been identified for dogs 
(Rozanski and Hoffman 1999), and loops can be evaluated for change in shape 
and corresponding parameters to identify respiratory abnormalities (Miller 2007; 
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Rozanski and Hoffman 1999). This may be one technique that could be applied 
to DM dogs to monitor changes in respiratory pattern caused by muscle 
weakness over the disease course.  
Another future direction would be to further assess pathologies at the 
molecular/cellular level occurring within DM motor neurons. Previous reports 
suggest that the SOD1 mutation associated with DM has a gain of function 
toxicity, in which SOD1 protein aggregation may be a key factor in the disease 
process (Crisp et al. 2013). The gain of function toxicity is supported by the 
normal enzymatic activity level retained by the mutant enzyme. In DM (Crisp et 
al. 2013) and in SOD1-ALS mice with low mutant copy numbers (Acevedo-
Arozena et al. 2011; Dal Canto and Gurney 1997; Henriques et al. 2010), gradual 
accumulation of insoluble aggregates over time has been reported. Although this 
association may not establish cause and effect, increase in aggregate 
accumulation tightly linked to disease severity may indicate a toxic association 
between disease progression and protein aggregation (Crisp et al. 2013; 
Matsumoto et al. 2005). This has been proposed in ALS (Bruijn et al. 1998; Deng 
et al. 2006; Matsumoto et al. 2005; Prudencio et al. 2009).  One potential way to 
evaluate aggregate involvement in DM is to prevent or slow the formation of 
aggregates and assess the change in aggregate formation with disease severity. 
Antisense oligonucleotide therapy involves the use of a ~20 nucleotide sequence 
construct which binds via Watson-Crick hybridization to its complementary 
mRNA sequence, causing the targeted mRNA to be degraded by RNase H 
(Smith et al. 2006). Administered intrathecally, antisense oligonucleotides 
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generated against SOD1 mRNA have been shown to be widely distributed in 
brain and spinal cord regions of mutant SOD1- ALS transgenic rats and non-
human primates (Smith et al. 2006). The construct penetrated into the nervous 
tissue, localized in spinal motor neurons and astrocytes, reduced SOD1 
expression, delayed disease progression, and extended survival (Smith et al. 
2006). Recently a phase 1 placebo –controlled clinical trial reported that 
antisense oligonucleotides were safe for application in human SOD1-ALS 
patients, (Miller et al. 2013) indicating that this approach may serve as a 
promising treatment for some forms of ALS.  Plans are underway to utilize this 
technology in DM-affected dogs, and because misfolded SOD1 in DM is prone to 
aggregate (Crisp et al. 2013), decreasing protein expression, by degrading SOD1 
mRNA, may in turn modulate aggregate formation. Filter trap assays have been 
used on mutant SOD1 rodent nervous tissue (Hishikawa et al. 2003; Wang et al. 
2003), and in vitro using cells expressing human (Matsumoto et al. 2005) and 
canine SOD1 mutations (Crisp et al. 2013) to assess aggregate formation. 
Additionally, Crisp et. al. employed western blotting analysis on spinal cord 
homogenates from DM affected dogs, and reported an increase in detergent-
insoluble mutant SOD1 which corresponded with disease severity (Crisp et al. 
2013). Similar protocols could be used for assessment of antisense 
oligonucleotide influence on SOD1 aggregation in DM-affected dogs. Results of 
which would be compared to disease severity to evaluate if (1) the treatment is 
capable of reducing SOD1 aggregates, and (2) to determine if that reduction 
affects disease phenotype. 
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General proprioceptive ataxia is an early clinical sign of DM (Averill 1973); 
however, as the disease progresses it is difficult to clinically separate the motor 
and sensory functional loss. Therefore, histological assessment may be a 
valuable tool in evaluating sensory involvement in DM.  
Sensory axon abnormalities have been reported in several ALS cases. 
Sural nerve biopsies (a purely sensory nerve) harvested from ALS patients early 
in the disease with no electrophysiological evidence of sensory involvement 
revealed significant morphometric changes in sural nerve studies compared to 
normal controls, suggesting early sensory axonal atrophy in ALS that may be 
masked by motor degeneration (Heads et al. 1991).  However axonal density 
was unchanged in this study, suggesting that axon drop out may occur later in 
the disease progression (Heads et al. 1991). Additionally, Giannini et.al.  
reported a progressive decrease in sensory action potential (SAP) amplitudes 
and sensory conduction velocities (SCV) in sural nerves from a FALS SOD1D90A 
patient (Andersen et al. 1995), indicating axonal loss and myelin degeneration. 
This observation was confirmed by a sural nerve biopsy revealing marked axonal 
degeneration and dropout (Giannini et al. 2010).  Progressive decreases in SAPs 
and SCVs have also been reported in sporadic ALS cases (Isaacs et al. 2007; 
Pugdahl et al. 2007). Interestingly, one patient was reported to have absent 
SAPs, although axonal loss in a sural nerve biopsy was mild with moderate 
myelin pathology (Isaacs et al. 2007). Taken together these results support the 
idea that ALS is a multisystem disease affecting the motor and sensory system. 
These data also suggest that sural nerve axonal loss may be a feature of late 
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disease (Heads et al. 1991), and functional loss may precede physical axon loss 
(Isaacs et al. 2007). To expand our histological assessment of the sensory 
system in DM, sural nerve biopsies could be harvest from early and late stage 
dogs for morphometric evaluation of myelinated axons. Additionally, 
electrodiagnostic evaluation of sural nerves could also be employed, to monitor 
the progression of sensory deficits. Also, to further evaluate dorsal root and DRG 
involvement in the DM disease progression, our analysis should be extended to 
other spinal segments, and should encompass early and late disease grades.  
Peripheral nerve axon loss in DM has been reported (Shelton et al. 2012). 
However, the nerve analyzed was a mixed nerve (common peroneal); 
consequently, it is still to be determined if the loss observed was due to loss of 
motor, sensory or both axon types.  To complement the work done by Shelton et. 
al., peroneal nerves could be subjected to double immunofluresence labeling 
using antibodies against ChAT and NF-L using a protocol previously described 
(Gay et al. 2012). With this method all axons would be labeled with anti NF-L, 
and only motor axons would be identified with ChAT labeling. Imaging analysis 
software could then be used on captured images to obtain counts of the total 
number of NF-L positive axons vs ChAT positive axons, allowing us to determine 
what proportion of the peroneal nerve axon population is motor vs. sensory 
fibers. One limitation with this method would be control over antigen availability. 
For instance, within a given motor axon segment ChAT antigen availability could 
be limited resulting in a false negative. One way to control for this would be to 
stain multiple sections per sample and/or to identify sensory axon specific 
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antibodies. This analysis would need to be conducted on early and late stage DM 
samples to evaluate the progression of axon loss.  
Summary 
 This study was the first report of respiratory muscle histopathology in DM, 
complementing recent findings that DM ultimately resulted in respiratory 
impairment (Ogawa et al. 2011; Ogawa et al. 2013). Our data also supported 
recent findings of LMN involvement in DM (Awano et al. 2009; Shelton et al. 
2012). Although no morphological defects were observed in thoracic spinal MN 
somas, the muscle pathology observed in the intercostal muscles was suggestive 
of MU pathology. Our findings of substantial sensory pathology in dorsal roots 
and dorsal root ganglia emphasized that DM was a multisystem disease 
encompassing the degeneration of both motor and sensory pathways. The 
results from this study significantly contribute to the study of canine DM and 
provide further insight into the similarities between DM and ALS patients with 
autosomal recessive SOD1 D90A ALS. Overall, we believe that canine DM is a 
reliable disease model for human ALS, and further studies using this model will 
contribute to our understanding of both diseases and development of effective 
treatments. 
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